MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 2 | 1.0 |
Embryo Transfer/*standards | 2 | 1.0 |
Female | 680 | 0.0 |
Humans | 2093 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 33 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Review Literature | 2 | 1.0 |
Acute Disease | 20 | 0.0 |
Adult | 438 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 3 | 3.0 |
Comparative Study | 210 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 3 | 3.0 |
Fetal Blood/transplantation | 3 | 3.0 |
Leukemia/*therapy | 3 | 2.0 |
Patient Selection | 3 | 1.0 |
Animals | 521 | 0.0 |
Oligonucleotide Array Sequence Analysis | 18 | 1.0 |
Aged | 385 | 1.0 |
Aged, 80 and over | 169 | 1.0 |
Balloon Dilatation/adverse effects/*instrumentation | 2 | 4.0 |
Esophageal and Gastric Varices/therapy | 2 | 4.0 |
Esophagus/*injuries/radiography | 2 | 4.0 |
Fatal Outcome | 3 | 0.0 |
Foreign Bodies/*radiography | 2 | 4.0 |
Gastrointestinal Hemorrhage/therapy | 2 | 4.0 |
*Medical Errors | 2 | 4.0 |
Pleural Cavity/*radiography | 2 | 4.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
Antigens, CD44/*metabolism | 190 | 98.0 |
Cadherins/*metabolism | 3 | 4.0 |
Diagnosis, Differential | 20 | 0.0 |
Immunohistochemistry | 363 | 2.0 |
Retrospective Studies | 41 | 1.0 |
Tumor Markers, Biological/*metabolism | 28 | 6.0 |
Antigens, CD31/metabolism | 2 | 2.0 |
Antigens, CD44/metabolism | 75 | 84.0 |
Cell Adhesion/drug effects | 42 | 9.0 |
*Cell Movement | 12 | 11.0 |
Cell Proliferation/drug effects | 3 | 3.0 |
Disease Progression | 69 | 2.0 |
Gene Expression Regulation, Neoplastic | 49 | 2.0 |
Mice | 294 | 0.0 |
Mice, Nude | 48 | 2.0 |
Microcirculation | 10 | 3.0 |
Neoplasm Invasiveness/*pathology | 3 | 11.0 |
*Neovascularization, Pathologic | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 1241 | 0.0 |
Tumor Cells, Cultured/transplantation | 2 | 6.0 |
Male | 521 | 0.0 |
Middle Aged | 452 | 0.0 |
Prognosis | 213 | 3.0 |
Time Factors | 51 | 0.0 |
*Osteogenesis | 3 | 13.0 |
RNA, Messenger/genetics/metabolism | 15 | 0.0 |
Rats | 70 | 0.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Receptors, Cell Surface/genetics/*metabolism | 6 | 4.0 |
Antigens, CD44/analysis | 57 | 77.0 |
*Antigens, Neoplasm | 3 | 1.0 |
Breast/chemistry | 2 | 9.0 |
Chi-Square Distribution | 6 | 0.0 |
Neoplasm Proteins/*analysis | 8 | 2.0 |
Receptors, Estrogen/analysis | 5 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 94 | 1.0 |
Tumor Markers, Biological/analysis | 21 | 2.0 |
Carcinoma, Squamous Cell/*metabolism/mortality/secondary | 2 | 50.0 |
Glycoproteins/*metabolism | 18 | 9.0 |
Laryngeal Neoplasms/*metabolism/mortality/pathology | 2 | 40.0 |
Neoplasm Recurrence, Local | 17 | 4.0 |
Neoplasm Staging | 89 | 3.0 |
Protein Isoforms/metabolism | 23 | 12.0 |
Survival Rate | 69 | 3.0 |
Biological Markers/analysis | 17 | 1.0 |
Cell Differentiation | 72 | 2.0 |
Cell Division | 87 | 1.0 |
Cell Movement | 57 | 6.0 |
Cell Polarity | 6 | 4.0 |
Fetus | 9 | 1.0 |
Antigens, CD29/physiology | 2 | 14.0 |
Antigens, CD44/physiology | 19 | 90.0 |
Cell Adhesion | 162 | 11.0 |
Cells, Cultured | 252 | 1.0 |
Dose-Response Relationship, Drug | 41 | 0.0 |
Drug Synergism | 6 | 0.0 |
Enzyme Inhibitors/pharmacology | 15 | 0.0 |
Extracellular Matrix Proteins/*metabolism | 4 | 6.0 |
Fibronectins/metabolism | 12 | 6.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Hyaluronic Acid/metabolism | 68 | 78.0 |
Imidazoles/pharmacology | 2 | 0.0 |
Interferon Type II/biosynthesis | 7 | 1.0 |
Interleukin-12/*pharmacology | 2 | 4.0 |
Interleukin-18/*pharmacology | 2 | 16.0 |
Pyridines/pharmacology | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Cell Adhesion/physiology | 39 | 13.0 |
Cell Communication/*physiology | 2 | 3.0 |
Down-Regulation | 43 | 2.0 |
Epidermal Growth Factor/pharmacology | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 411 | 0.0 |
Signal Transduction/physiology | 8 | 0.0 |
Solubility | 35 | 2.0 |
Cell Division/drug effects | 33 | 0.0 |
Culture Media, Conditioned/metabolism | 2 | 6.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
Hyaluronic Acid/*pharmacology | 24 | 72.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Neoplasm Invasiveness/pathology | 5 | 8.0 |
Phosphorylation/drug effects | 8 | 0.0 |
Precipitin Tests | 28 | 0.0 |
Receptor, erbB-2/metabolism | 2 | 1.0 |
Tumor Cells, Cultured | 359 | 2.0 |
Urinary Plasminogen Activator/metabolism | 2 | 4.0 |
Adenocarcinoma/genetics/metabolism/*pathology | 2 | 10.0 |
Alternative Splicing | 67 | 6.0 |
Colonic Neoplasms/genetics/metabolism/*pathology | 3 | 27.0 |
Neoplasm Metastasis | 84 | 8.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
RNA, Messenger/genetics | 48 | 1.0 |
RNA, Neoplasm/genetics | 14 | 4.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Transcription, Genetic/drug effects | 5 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 10 | 0.0 |
Antigens, CD44/biosynthesis | 26 | 78.0 |
*Apoptosis | 11 | 0.0 |
In Situ Nick-End Labeling | 5 | 0.0 |
Ki-67 Antigen/metabolism | 3 | 1.0 |
Protein p53/biosynthesis | 6 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 5 | 3.0 |
Tumor Markers, Biological/*biosynthesis | 8 | 9.0 |
Antigens, CD44/genetics/*metabolism | 53 | 100.0 |
Fluorescent Antibody Technique | 55 | 2.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Neoplasm Invasiveness | 101 | 8.0 |
Phenotype | 89 | 0.0 |
Phorbol Esters/pharmacology | 3 | 2.0 |
Phosphoproteins/genetics/*metabolism | 2 | 1.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Antigens, CD44/*immunology | 32 | 100.0 |
Bile Ducts/*immunology | 2 | 66.0 |
Case-Control Studies | 19 | 0.0 |
Cell Separation | 28 | 2.0 |
Epithelial Cells/immunology | 3 | 8.0 |
Liver Cirrhosis, Biliary/immunology | 2 | 13.0 |
Protein Binding | 61 | 0.0 |
Statistics, Nonparametric | 8 | 0.0 |
Cell Adhesion Molecules/genetics/metabolism | 4 | 9.0 |
*Oligonucleotide Array Sequence Analysis | 5 | 2.0 |
Antigens, CD44/*analysis | 93 | 92.0 |
Cadherins/*analysis | 7 | 31.0 |
Tumor Markers, Biological/*analysis | 45 | 4.0 |
Adolescent | 89 | 0.0 |
Biocompatible Materials/pharmacology | 2 | 16.0 |
Cell Movement/drug effects/*physiology | 3 | 6.0 |
Collagen/pharmacology | 5 | 3.0 |
Drug Combinations | 15 | 2.0 |
Inflammation Mediators/metabolism | 2 | 2.0 |
Interleukin-5/pharmacology | 4 | 15.0 |
Laminin/pharmacology | 4 | 9.0 |
Predictive Value of Tests | 28 | 1.0 |
Proteoglycans/pharmacology | 3 | 7.0 |
COS Cells | 9 | 0.0 |
Cattle | 22 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 4 | 0.0 |
Extracellular Matrix/*metabolism | 7 | 7.0 |
Genes, Reporter/genetics | 3 | 1.0 |
Hyaluronoglucosaminidase/pharmacology | 17 | 70.0 |
Mutagenesis, Site-Directed | 12 | 0.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Transfection | 107 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Genes, Dominant | 3 | 0.0 |
Hela Cells | 14 | 0.0 |
Microfilament Proteins/metabolism | 3 | 3.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 4 | 1.0 |
Tissue Distribution | 17 | 0.0 |
Apoptosis | 25 | 1.0 |
Base Sequence | 163 | 0.0 |
Cell Survival/*physiology | 2 | 3.0 |
DNA Primers | 35 | 0.0 |
Lung Neoplasms/secondary | 7 | 8.0 |
*Neoplasm Metastasis | 18 | 21.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 93 | 0.0 |
Flow Cytometry | 214 | 3.0 |
Leukocytes, Mononuclear/immunology/metabolism | 2 | 4.0 |
Skin Tests | 2 | 1.0 |
Amino Acid Sequence | 103 | 0.0 |
Antibodies, Monoclonal | 78 | 3.0 |
Antigens, CD44/immunology/*metabolism | 16 | 94.0 |
Cell Movement/*physiology | 15 | 7.0 |
Melanoma | 6 | 6.0 |
Mice, Inbred BALB C | 48 | 1.0 |
Molecular Sequence Data | 211 | 0.0 |
Phosphoproteins/*metabolism | 7 | 1.0 |
Protein Kinase C/*metabolism | 4 | 1.0 |
Serine/metabolism | 2 | 0.0 |
Carcinogenicity Tests | 3 | 3.0 |
Gene Expression | 72 | 1.0 |
Neoplasm Proteins/metabolism | 10 | 2.0 |
Neoplasm Transplantation | 31 | 2.0 |
Blotting, Western | 79 | 1.0 |
Cell Adhesion Molecules/*metabolism | 55 | 20.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Hyaluronic Acid/*metabolism | 97 | 88.0 |
Apoptosis/drug effects | 4 | 0.0 |
Binding Sites | 34 | 0.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Hyaluronic Acid/metabolism/*pharmacology | 3 | 75.0 |
Transplantation, Heterologous | 22 | 2.0 |
Antigens, CD44/*genetics | 61 | 96.0 |
*Exons | 14 | 3.0 |
Glycoproteins/*genetics | 3 | 1.0 |
Antigens, CD/*metabolism | 11 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
Biological Markers | 22 | 1.0 |
Blood Cells/metabolism | 2 | 6.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 2 | 5.0 |
Intercellular Adhesion Molecule-1/analysis | 15 | 13.0 |
Interleukin-3/*pharmacology | 4 | 3.0 |
Up-Regulation | 49 | 2.0 |
Antigens, CD45/biosynthesis | 4 | 7.0 |
Cell Differentiation/genetics/immunology | 3 | 3.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Mice, Inbred C57BL | 42 | 1.0 |
Mice, Transgenic | 13 | 0.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Signal Transduction/genetics/immunology | 2 | 2.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Antigens, CD44/*biosynthesis | 62 | 93.0 |
Epitopes | 14 | 1.0 |
Glycoproteins/*biosynthesis | 8 | 16.0 |
Kinetics | 40 | 0.0 |
Neoplasms/*therapy | 2 | 1.0 |
Protein Structure, Tertiary | 28 | 0.0 |
Recombinant Fusion Proteins/metabolism | 9 | 0.0 |
Antigens, CD40/*metabolism | 2 | 4.0 |
Biopsy, Needle | 12 | 2.0 |
Cell Count | 10 | 1.0 |
Immunoenzyme Techniques | 97 | 2.0 |
Lymph Nodes/pathology | 7 | 2.0 |
Lymphatic Metastasis | 63 | 6.0 |
Skin Neoplasms/*metabolism/mortality/pathology | 2 | 100.0 |
Survival Analysis | 41 | 1.0 |
Tumor Markers, Biological/metabolism | 9 | 2.0 |
*Alternative Splicing | 56 | 9.0 |
Antigens, CD44/biosynthesis/*genetics | 16 | 100.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Protein Isoforms | 35 | 5.0 |
RNA | 2 | 4.0 |
Antigens, CD44/*biosynthesis/genetics | 22 | 100.0 |
Cell Line | 151 | 0.0 |
Culture Media | 7 | 1.0 |
Lactic Acid/*pharmacology | 2 | 28.0 |
RNA, Messenger/biosynthesis | 22 | 1.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
Antibodies, Monoclonal/immunology/pharmacology | 7 | 7.0 |
Apoptosis/*drug effects | 5 | 0.0 |
Cell Adhesion Molecules/metabolism | 35 | 14.0 |
Fibroblasts/cytology/drug effects | 2 | 5.0 |
Jurkat Cells | 7 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 8 | 5.0 |
Basement Membrane/metabolism | 4 | 6.0 |
Enzyme Activation | 11 | 0.0 |
Fibroblasts/metabolism | 6 | 0.0 |
Gelatinase A/*metabolism | 2 | 6.0 |
*Gene Expression Regulation, Neoplastic | 29 | 2.0 |
Metalloendopeptidases/metabolism | 4 | 6.0 |
Models, Biological | 29 | 0.0 |
Glycoproteins/*analysis | 6 | 8.0 |
*Prostatectomy | 4 | 14.0 |
Child | 72 | 0.0 |
Child, Preschool | 51 | 0.0 |
English Abstract | 103 | 0.0 |
Introns/genetics | 2 | 0.0 |
Apoptosis/physiology | 6 | 1.0 |
Cell Culture Techniques/methods | 8 | 3.0 |
Cell Transplantation | 2 | 2.0 |
Receptors, Interleukin-2/metabolism | 8 | 4.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Antigens, CD44/chemistry/genetics/*physiology | 8 | 100.0 |
Cell Movement/physiology | 21 | 9.0 |
Matrix Metalloproteinases/metabolism | 2 | 4.0 |
Molecular Structure | 4 | 0.0 |
Cell Adhesion Molecules/genetics | 3 | 6.0 |
Cell Differentiation/drug effects | 14 | 1.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Fibroblasts/cytology/drug effects/metabolism | 3 | 5.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Antigens, CD44/*physiology | 49 | 100.0 |
Bleomycin | 2 | 25.0 |
Chemokines/genetics/metabolism | 2 | 18.0 |
Chimera | 2 | 1.0 |
Neutrophils | 2 | 2.0 |
Phagocytosis | 3 | 0.0 |
Transforming Growth Factor beta/metabolism | 5 | 2.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Integrins/metabolism | 24 | 14.0 |
Intercellular Adhesion Molecule-1/metabolism | 20 | 10.0 |
Receptors, Collagen | 6 | 8.0 |
Gene Expression Regulation | 30 | 0.0 |
Immunoglobulin G | 2 | 1.0 |
Lymph Nodes/cytology | 4 | 9.0 |
Mice, Knockout | 16 | 0.0 |
RNA, Messenger/metabolism | 37 | 0.0 |
Receptors, Lymphocyte Homing/*metabolism | 20 | 64.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 9 | 10.0 |
Glycoproteins/immunology/*metabolism | 3 | 16.0 |
Multivariate Analysis | 26 | 1.0 |
*Neoplasm Circulating Cells | 5 | 12.0 |
Stomach Neoplasms/*immunology/mortality/pathology | 2 | 66.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Ligands | 46 | 1.0 |
Lipopolysaccharides/*pharmacology | 5 | 1.0 |
RANTES/metabolism/*pharmacology | 2 | 66.0 |
Transcription, Genetic/immunology | 4 | 5.0 |
Antigens, CD/metabolism | 26 | 2.0 |
Antigens, CD45/metabolism | 5 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 7 | 6.0 |
Antigens, Surface/*metabolism | 3 | 5.0 |
Cytokines/pharmacology | 16 | 4.0 |
Inflammation/immunology | 4 | 3.0 |
Macrophage-1 Antigen/metabolism | 5 | 7.0 |
Carcinoma, Basal Cell/*metabolism/pathology | 2 | 20.0 |
Microscopy, Immunoelectron | 12 | 2.0 |
Skin Neoplasms/*metabolism/pathology | 6 | 9.0 |
Microscopy, Confocal | 14 | 1.0 |
Receptor, erbB-2/*metabolism | 5 | 3.0 |
Analysis of Variance | 10 | 0.0 |
*Antigens, CD44/analysis | 2 | 100.0 |
Disease-Free Survival | 33 | 3.0 |
Odds Ratio | 2 | 0.0 |
Proportional Hazards Models | 11 | 1.0 |
Carrier Proteins/metabolism | 12 | 1.0 |
Mutation | 26 | 0.0 |
Phosphoproteins/metabolism | 6 | 0.0 |
Phosphorylation | 28 | 0.0 |
Serine/*metabolism | 2 | 2.0 |
Antibodies, Monoclonal/*pharmacology | 9 | 4.0 |
Leukemia, Myelocytic, Acute/immunology/*pathology | 2 | 15.0 |
Bone Marrow Cells/*cytology | 5 | 10.0 |
Cell Differentiation/physiology | 13 | 2.0 |
Hematopoietic Stem Cells/*cytology | 6 | 2.0 |
Skin/*cytology | 3 | 6.0 |
Extracellular Matrix/metabolism | 25 | 13.0 |
Neoplasms/*metabolism | 2 | 2.0 |
Neovascularization, Pathologic/metabolism | 2 | 2.0 |
*Tumor Markers, Biological | 12 | 6.0 |
Virulence | 2 | 0.0 |
Apoptosis/genetics/immunology | 2 | 25.0 |
Crosses, Genetic | 2 | 0.0 |
DNA-Binding Proteins/biosynthesis | 2 | 2.0 |
Immunophenotyping | 95 | 3.0 |
Receptors, Chemokine/biosynthesis | 2 | 4.0 |
Receptors, Interleukin-2/*biosynthesis | 3 | 7.0 |
Colorectal Neoplasms/*chemistry/pathology | 3 | 18.0 |
Intestinal Mucosa/chemistry | 2 | 7.0 |
*Reverse Transcriptase Polymerase Chain Reaction | 5 | 8.0 |
Antigens, CD44/analysis/*biosynthesis | 24 | 100.0 |
Risk Assessment | 5 | 0.0 |
Protein Isoforms/analysis | 11 | 26.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Antigens, CD44/*genetics/metabolism | 11 | 100.0 |
Cell Survival/drug effects | 11 | 1.0 |
DNA Primers/chemistry | 24 | 2.0 |
Exons | 71 | 1.0 |
Gene Expression Regulation, Neoplastic/*genetics | 5 | 2.0 |
*Gene Therapy | 3 | 0.0 |
Introns | 8 | 0.0 |
Plasmids | 5 | 0.0 |
Polymerase Chain Reaction | 115 | 0.0 |
Antibodies, Monoclonal/*immunology/metabolism | 2 | 10.0 |
Binding, Competitive | 9 | 0.0 |
Epitopes/metabolism | 3 | 5.0 |
Cell Cycle | 11 | 0.0 |
Cyclin A/metabolism | 3 | 3.0 |
DNA/biosynthesis | 5 | 0.0 |
*Down-Regulation | 7 | 2.0 |
Nuclear Proteins/genetics/*metabolism | 2 | 0.0 |
*RNA-Binding Proteins | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
*DNA-Binding Proteins | 5 | 0.0 |
Gene Expression Profiling | 17 | 1.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
*Signal Transduction | 13 | 0.0 |
Biopsy | 19 | 1.0 |
Major Histocompatibility Complex | 2 | 0.0 |
Integrins/*metabolism | 10 | 6.0 |
Signal Transduction | 36 | 0.0 |
Fibroblast Growth Factor 2/metabolism | 3 | 3.0 |
Bone Marrow Cells/*immunology | 5 | 18.0 |
Clone Cells | 18 | 1.0 |
Plasma Cells/*immunology | 4 | 14.0 |
Brain/metabolism | 3 | 0.0 |
Neoplasms/pathology/*physiopathology | 3 | 50.0 |
Transcription, Genetic | 30 | 0.0 |
*Genes, Tumor Suppressor | 9 | 0.0 |
*Mutation | 9 | 0.0 |
Antigens, CD44/analysis/immunology | 2 | 100.0 |
CHO Cells | 11 | 0.0 |
Cercopithecus aethiops | 6 | 0.0 |
Hamsters | 18 | 0.0 |
Lymphocyte Activation/*immunology | 10 | 2.0 |
Signal Transduction/*immunology | 6 | 1.0 |
T-Lymphocytes/cytology/*immunology | 3 | 2.0 |
Antigens, CD44/genetics/metabolism | 9 | 69.0 |
Chick Embryo | 4 | 0.0 |
Extracellular Matrix/drug effects/physiology | 3 | 50.0 |
Sequence Homology | 2 | 0.0 |
Tretinoin/pharmacology | 6 | 1.0 |
Chondrocytes/metabolism | 4 | 10.0 |
Cytokines/metabolism | 7 | 1.0 |
Lysosomes/*metabolism | 2 | 2.0 |
Receptors, Cell Surface/*metabolism | 14 | 2.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 36 | 0.0 |
Peptides/chemistry | 3 | 0.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
Chondroitin Sulfates/*metabolism | 4 | 28.0 |
Dermatan Sulfate/*metabolism | 3 | 75.0 |
L-Selectin/*metabolism | 9 | 39.0 |
Oligosaccharides/*metabolism | 3 | 11.0 |
P-Selectin/*metabolism | 2 | 9.0 |
Antigens, CD44/biosynthesis/genetics | 3 | 100.0 |
DNA Probes | 5 | 0.0 |
Growth Substances/biosynthesis/genetics | 2 | 12.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Cathepsin D/*analysis | 3 | 15.0 |
Risk Factors | 14 | 0.0 |
Antigens, CD44/biosynthesis/*physiology | 7 | 100.0 |
Cell Adhesion/drug effects/physiology | 6 | 10.0 |
Epithelial Cells/pathology | 2 | 2.0 |
Hyaluronic Acid/pharmacology | 15 | 88.0 |
Oligopeptides/pharmacology | 3 | 1.0 |
Ovarian Neoplasms/metabolism/*pathology | 5 | 31.0 |
Cell Adhesion/*drug effects | 9 | 16.0 |
Cell Adhesion Molecules/*biosynthesis | 22 | 25.0 |
Fluorescent Antibody Technique, Indirect | 22 | 2.0 |
Age Factors | 10 | 0.0 |
Gene Amplification | 10 | 1.0 |
Infant | 49 | 0.0 |
Tumor Markers, Biological | 28 | 6.0 |
Antigens, CD44/*blood | 23 | 100.0 |
Cell Line, Tumor | 32 | 1.0 |
Fibrosarcoma | 4 | 8.0 |
Hyaluronic Acid/*metabolism/pharmacology | 10 | 83.0 |
*Antigens, CD | 29 | 3.0 |
*Antigens, Differentiation | 11 | 11.0 |
Cell Adhesion Molecules/metabolism/physiology | 3 | 60.0 |
Cell Aggregation | 12 | 11.0 |
Cell Polarity/*physiology | 3 | 12.0 |
Chemotaxis, Leukocyte | 4 | 2.0 |
Cytoskeleton/metabolism | 9 | 3.0 |
Microscopy, Fluorescence | 18 | 1.0 |
Protein Transport | 2 | 0.0 |
Fibroblasts/*metabolism | 3 | 1.0 |
*Gene Expression | 11 | 1.0 |
Karyotyping | 13 | 0.0 |
RNA, Messenger/analysis | 44 | 1.0 |
Immunohistochemistry/methods | 13 | 1.0 |
Vascular Endothelial Growth Factor A | 5 | 0.0 |
Vascular Endothelial Growth Factors | 5 | 0.0 |
Follow-Up Studies | 39 | 1.0 |
Hyaluronic Acid/*analysis | 14 | 70.0 |
Stromal Cells/chemistry | 3 | 13.0 |
Point Mutation | 2 | 0.0 |
Proteoglycans/metabolism | 4 | 5.0 |
*DNA Methylation | 10 | 1.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Glycoproteins/genetics/metabolism | 2 | 8.0 |
Antigens, CD29/analysis | 6 | 28.0 |
Antigens, CD34/analysis | 12 | 1.0 |
Antigens, CD45/analysis | 9 | 3.0 |
HLA-DR Antigens/analysis | 14 | 2.0 |
Histocytochemistry | 5 | 0.0 |
Antigens, CD/analysis | 43 | 2.0 |
Antigens, CD56/*analysis | 3 | 9.0 |
Antigens, Differentiation/*analysis | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 8 | 2.0 |
Cell Adhesion Molecules/analysis | 26 | 16.0 |
Lymphocyte Activation | 65 | 2.0 |
Receptors, Immunologic/analysis | 9 | 10.0 |
Receptors, Lymphocyte Homing/analysis | 26 | 78.0 |
Antibodies, Monoclonal/metabolism | 9 | 2.0 |
Antigens, CD44/biosynthesis/*metabolism | 6 | 100.0 |
Biotinylation | 7 | 4.0 |
Blotting, Northern | 31 | 0.0 |
Cell Membrane/metabolism | 29 | 1.0 |
Cross-Linking Reagents/pharmacology | 3 | 2.0 |
Dimerization | 3 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 47 | 2.0 |
Antigens, CD44/*analysis/genetics | 20 | 100.0 |
Gastric Mucosa/chemistry | 3 | 17.0 |
Antigens, CD44/biosynthesis/physiology | 2 | 100.0 |
*Cell Communication | 5 | 6.0 |
Epithelium/physiology | 5 | 5.0 |
Integrins/*physiology | 17 | 20.0 |
Peritoneum/cytology | 2 | 28.0 |
Antigens, Neoplasm/genetics | 2 | 7.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Azacitidine/*pharmacology | 2 | 12.0 |
*Neoplasm Proteins | 2 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Phosphoprotein Phosphatase/genetics | 2 | 12.0 |
RNA, Messenger/*analysis | 9 | 2.0 |
Transcription Factors/genetics | 2 | 0.0 |
Antigens, CD44/analysis/metabolism | 3 | 100.0 |
Sialoglycoproteins/analysis/*biosynthesis | 2 | 100.0 |
Antigens, Neoplasm/*metabolism | 16 | 16.0 |
Hyaluronic Acid/analysis | 3 | 33.0 |
Reproducibility of Results | 6 | 0.0 |
Antigens, CD44/immunology/*physiology | 11 | 100.0 |
*Cell Differentiation/drug effects | 2 | 6.0 |
Antigens, CD/*genetics | 6 | 2.0 |
Gene Expression Regulation, Neoplastic/drug effects | 6 | 1.0 |
Protein Isoforms/genetics | 5 | 1.0 |
*Variation (Genetics) | 25 | 2.0 |
E-Selectin/metabolism | 5 | 10.0 |
Glycosylation | 26 | 2.0 |
Neoplasms/*pathology | 6 | 11.0 |
Tandem Repeat Sequences | 2 | 1.0 |
Antigens, CD18/physiology | 4 | 33.0 |
Chemiluminescent Measurements | 4 | 2.0 |
Hyaluronic Acid/*physiology | 14 | 82.0 |
Monocytes/*physiology | 4 | 2.0 |
Neoplasms/metabolism/*pathology | 2 | 14.0 |
Cell Lineage | 9 | 2.0 |
Chromosome Mapping | 4 | 0.0 |
Mice, SCID | 31 | 3.0 |
Nucleic Acid Hybridization | 8 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Receptors, Estrogen/biosynthesis | 2 | 4.0 |
Vimentin/biosynthesis | 2 | 14.0 |
Severity of Illness Index | 4 | 0.0 |
Molecular Mimicry | 2 | 2.0 |
Protein-Tyrosine Kinase/metabolism | 5 | 0.0 |
Streptococcus pyogenes/*pathogenicity | 2 | 66.0 |
rac1 GTP-Binding Protein/metabolism | 2 | 2.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 2 | 5.0 |
In Vitro | 50 | 0.0 |
Macrophages, Alveolar/*immunology/metabolism | 2 | 33.0 |
Dinoprostone/metabolism | 2 | 2.0 |
RNA/analysis | 4 | 1.0 |
Cell Differentiation/immunology | 10 | 3.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Signal Transduction/genetics/*immunology | 2 | 2.0 |
Proteins/*metabolism | 7 | 0.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Caspases/metabolism | 4 | 0.0 |
DNA/metabolism | 4 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 3 | 1.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Neuroblastoma/*genetics | 2 | 2.0 |
Antigens, CD/physiology | 20 | 9.0 |
Antigens, CD29/*physiology | 4 | 19.0 |
Cell Adhesion/*physiology | 18 | 15.0 |
Cell Division/physiology | 14 | 1.0 |
Collagen Type IV/metabolism | 2 | 9.0 |
Extracellular Matrix Proteins/metabolism | 11 | 11.0 |
Integrin alpha5 | 4 | 21.0 |
Laminin/metabolism | 9 | 8.0 |
Antigens, CD11/analysis | 4 | 13.0 |
Antigens, CD18/analysis | 5 | 23.0 |
Endothelium, Vascular/*immunology | 5 | 5.0 |
Intercellular Adhesion Molecule-1/blood | 3 | 3.0 |
Lymphocytes/*immunology | 14 | 3.0 |
Neutrophils/*physiology | 6 | 4.0 |
Sialoglycoproteins/analysis | 4 | 10.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Antigens, CD44/*analysis/metabolism | 2 | 100.0 |
Protein Binding/immunology | 6 | 3.0 |
Antineoplastic Agents/pharmacology | 5 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 17 | 0.0 |
Immunoblotting | 23 | 0.0 |
Plasmids/metabolism | 5 | 0.0 |
S Phase | 3 | 0.0 |
Apoptosis/genetics | 3 | 1.0 |
Culture Media/pharmacology | 2 | 2.0 |
DNA, Complementary/genetics | 12 | 0.0 |
Expressed Sequence Tags | 5 | 1.0 |
Glioma/*pathology | 5 | 9.0 |
Lasers | 2 | 1.0 |
Neoplasm Invasiveness/*genetics | 5 | 14.0 |
Neoplasm Proteins/*biosynthesis/genetics | 4 | 2.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Antibodies, Monoclonal/pharmacology | 31 | 4.0 |
Astrocytoma/metabolism/pathology | 2 | 28.0 |
Brain Neoplasms/*metabolism/pathology | 3 | 6.0 |
Glioma/*metabolism/pathology | 2 | 7.0 |
Molecular Weight | 38 | 1.0 |
Neoplasm Invasiveness/*physiopathology | 4 | 22.0 |
Genes, Reporter | 3 | 0.0 |
Ionomycin/pharmacology | 7 | 3.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Transcription, Genetic/physiology | 2 | 1.0 |
*Extracellular Matrix Proteins | 7 | 5.0 |
Glucuronosyltransferase/biosynthesis/genetics | 2 | 40.0 |
In Situ Hybridization | 11 | 0.0 |
Interleukin-1/pharmacology | 13 | 2.0 |
Oligonucleotides, Antisense/*pharmacology | 3 | 3.0 |
Disease Models, Animal | 17 | 0.0 |
T-Lymphocytes/immunology | 10 | 0.0 |
Endometrium/cytology/*physiology | 2 | 16.0 |
Stromal Cells/physiology | 5 | 9.0 |
Antigens, CD44/biosynthesis/genetics/immunology/*physiology | 2 | 100.0 |
Fibroblasts/cytology | 6 | 2.0 |
*Glycosyltransferases | 9 | 24.0 |
*Membrane Proteins | 13 | 1.0 |
Protein Isoforms/biosynthesis/genetics | 7 | 12.0 |
Recombinant Fusion Proteins/physiology | 3 | 1.0 |
*Transferases | 9 | 24.0 |
Tumor Necrosis Factor-alpha/pharmacology | 29 | 2.0 |
*Xenopus Proteins | 9 | 2.0 |
Actins/metabolism | 12 | 2.0 |
Cytoskeleton/*metabolism | 8 | 6.0 |
Sialoglycoproteins/metabolism | 4 | 8.0 |
Antigens, CD44/analysis/*metabolism | 6 | 100.0 |
Urothelium/pathology | 2 | 28.0 |
Antigens, CD44/genetics | 14 | 73.0 |
RNA, Messenger/*genetics | 4 | 1.0 |
Tumor Markers, Biological/*genetics | 3 | 2.0 |
Inflammation Mediators/*physiology | 2 | 8.0 |
Interferon Type II/pharmacology | 15 | 2.0 |
Monocytes/*metabolism | 7 | 1.0 |
Sulfates/metabolism | 4 | 7.0 |
Blotting, Southern | 40 | 1.0 |
Chromosomes, Human, Pair 14 | 3 | 1.0 |
Cloning, Molecular | 31 | 0.0 |
DNA, Neoplasm | 3 | 2.0 |
Genes, p53 | 6 | 1.0 |
Genes, ras | 5 | 2.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Multiple Myeloma/genetics/immunology/*pathology | 3 | 60.0 |
Sequence Homology, Nucleic Acid | 13 | 0.0 |
Translocation, Genetic | 5 | 0.0 |
Chronic Disease | 16 | 0.0 |
Glycoproteins/*blood | 2 | 2.0 |
Receptors, Interleukin-2/blood | 4 | 5.0 |
Smoking | 4 | 1.0 |
Microscopy, Electron | 16 | 0.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
Antibodies, Monoclonal/immunology/metabolism | 2 | 4.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Receptor, erbB-2/genetics/*metabolism | 2 | 6.0 |
Signal Transduction/*physiology | 16 | 1.0 |
Cervix Neoplasms/*metabolism | 4 | 12.0 |
Adenocarcinoma/metabolism/pathology | 4 | 7.0 |
Cadherins/biosynthesis | 4 | 14.0 |
Carcinoma, Squamous Cell/metabolism/*pathology | 4 | 14.0 |
Cell Adhesion Molecules/biosynthesis | 11 | 13.0 |
RNA, Messenger/biosynthesis/genetics | 7 | 1.0 |
Stromal Cells/metabolism/pathology | 2 | 4.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 3 | 5.0 |
Breast Neoplasms/*metabolism | 3 | 1.0 |
Endometrial Neoplasms/*metabolism | 2 | 6.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Medroxyprogesterone 17-Acetate/pharmacology | 2 | 6.0 |
DNA, Neoplasm/genetics | 11 | 1.0 |
Prostatic Neoplasms/*genetics/pathology | 4 | 4.0 |
Cytotoxicity, Immunologic | 9 | 0.0 |
Immune Tolerance | 2 | 0.0 |
Lung Neoplasms/*immunology | 4 | 8.0 |
Models, Immunological | 4 | 1.0 |
Collagen Type I/metabolism | 2 | 5.0 |
Glycosaminoglycans/*metabolism | 3 | 13.0 |
Membrane Glycoproteins/genetics/*metabolism | 3 | 1.0 |
Ovarian Neoplasms/*metabolism | 2 | 3.0 |
Tumor Cells, Cultured/metabolism | 4 | 2.0 |
Adipose Tissue/*cytology | 2 | 40.0 |
Stem Cells/cytology | 2 | 2.0 |
Antigens, CD44/analysis/genetics | 2 | 100.0 |
Integrin alpha2 | 4 | 20.0 |
Integrin alpha6 | 2 | 10.0 |
Glycoproteins/metabolism | 7 | 4.0 |
Lung Neoplasms/*metabolism/pathology | 4 | 5.0 |
Precancerous Conditions/*metabolism/pathology | 2 | 9.0 |
Neoplasm Proteins/analysis | 5 | 1.0 |
P-Glycoprotein/analysis | 2 | 8.0 |
Protein p53/analysis | 9 | 3.0 |
ADP-ribosyl Cyclase | 11 | 2.0 |
Antigens, CD95/metabolism | 2 | 1.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Arthritis, Rheumatoid/immunology | 3 | 3.0 |
Germinal Center/*immunology | 2 | 33.0 |
Immunologic Memory | 10 | 3.0 |
Tonsil/immunology | 5 | 7.0 |
Apoptosis/*physiology | 4 | 0.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
Combined Modality Therapy | 7 | 0.0 |
*Gene Expression Profiling | 8 | 1.0 |
Glycosaminoglycans/metabolism | 8 | 17.0 |
Transforming Growth Factor beta/*metabolism | 3 | 1.0 |
Lymphocytes/metabolism/pathology | 2 | 11.0 |
Macrophages/metabolism/pathology | 2 | 7.0 |
Carbohydrate Sequence | 6 | 1.0 |
Animals, Genetically Modified | 2 | 0.0 |
Cell Size | 5 | 1.0 |
Gene Expression Regulation, Developmental | 5 | 0.0 |
Proteins/genetics | 4 | 0.0 |
Transforming Growth Factor beta/pharmacology | 7 | 2.0 |
Adenocarcinoma/immunology | 5 | 11.0 |
Fetus/immunology | 4 | 11.0 |
Cell Transformation, Neoplastic | 11 | 1.0 |
Cytoskeletal Proteins/genetics/*metabolism | 2 | 3.0 |
DNA, Neoplasm/analysis | 13 | 1.0 |
Mucous Membrane/metabolism/pathology | 2 | 16.0 |
Oligonucleotide Probes/chemistry | 2 | 6.0 |
*Trans-Activators | 6 | 0.0 |
Adenocarcinoma/*immunology/pathology | 4 | 20.0 |
Gallbladder Neoplasms/*immunology/pathology | 2 | 50.0 |
Breast Neoplasms/*metabolism/pathology | 6 | 3.0 |
Oncogenes/*physiology | 2 | 12.0 |
Cadherins/metabolism | 11 | 9.0 |
Cytoskeletal Proteins/metabolism | 7 | 2.0 |
Image Cytometry | 2 | 16.0 |
Neoplasm Proteins/*metabolism | 21 | 4.0 |
Ploidies | 8 | 3.0 |
Prostatic Neoplasms/*metabolism/pathology | 3 | 3.0 |
Antigens, Neoplasm/analysis/*metabolism | 2 | 100.0 |
Cohort Studies | 10 | 0.0 |
Probability | 5 | 0.0 |
Sensitivity and Specificity | 34 | 1.0 |
Antigens, CD/biosynthesis/genetics | 3 | 8.0 |
Cell Aggregation/drug effects | 5 | 11.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Intercellular Adhesion Molecule-1/*biosynthesis/genetics | 2 | 10.0 |
Killer Cells, Natural/drug effects | 2 | 5.0 |
Protein Conformation | 11 | 0.0 |
Signal Transduction/drug effects | 6 | 0.0 |
Antigens, CD4/analysis | 4 | 0.0 |
Antigens, CD8/analysis | 3 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 2 | 4.0 |
Receptors, Interleukin-2/analysis | 7 | 2.0 |
T-Lymphocytes/*immunology | 37 | 1.0 |
Thymus Gland/*cytology | 4 | 7.0 |
Placenta/*chemistry | 2 | 5.0 |
Cytokines/analysis | 3 | 4.0 |
Leukocytes, Mononuclear/immunology | 4 | 1.0 |
Th1 Cells/immunology | 4 | 2.0 |
Antigens, CD34/*analysis | 5 | 1.0 |
Cadherins/analysis | 5 | 15.0 |
Colorectal Neoplasms/*pathology | 4 | 6.0 |
Antibodies/immunology | 7 | 2.0 |
Gene Expression Regulation, Neoplastic/genetics | 4 | 2.0 |
Lung Neoplasms/*genetics/metabolism/pathology | 2 | 9.0 |
*Cell Differentiation | 4 | 1.0 |
Prostatic Neoplasms/*pathology | 2 | 1.0 |
Sialoglycoproteins/*metabolism | 8 | 28.0 |
Gene Expression/drug effects | 5 | 0.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 3 | 1.0 |
Cell Membrane/drug effects/metabolism | 2 | 2.0 |
Cell Movement/drug effects | 10 | 2.0 |
B-Lymphocytes/immunology/*pathology | 2 | 7.0 |
Cell Culture Techniques | 10 | 2.0 |
Coculture Techniques | 21 | 3.0 |
*Immunophenotyping | 9 | 5.0 |
Interleukin-7/pharmacology | 3 | 6.0 |
Leukemia, Lymphocytic, Acute/*immunology | 3 | 11.0 |
Stromal Cells | 2 | 5.0 |
DNA Mutational Analysis | 2 | 0.0 |
*Gene Expression Regulation, Leukemic | 3 | 3.0 |
*Genes, Immunoglobulin | 3 | 1.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
Immunoglobulins, Heavy-Chain/genetics | 4 | 2.0 |
Leukemia, Lymphocytic, Chronic/*genetics/metabolism | 2 | 50.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Intermediate Filament Proteins/analysis | 2 | 5.0 |
Adenocarcinoma/*metabolism/pathology | 8 | 6.0 |
Cadherins/*biosynthesis | 5 | 15.0 |
Cell Differentiation/*drug effects | 3 | 1.0 |
Colonic Neoplasms/*metabolism/pathology | 3 | 7.0 |
Macromolecular Substances | 8 | 0.0 |
Protein Binding/drug effects | 4 | 1.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Adjuvants, Immunologic/physiology | 3 | 6.0 |
Apoptosis/drug effects/immunology | 2 | 11.0 |
Arthritis, Rheumatoid/*immunology/metabolism/pathology | 2 | 28.0 |
Dose-Response Relationship, Immunologic | 7 | 1.0 |
Synovial Membrane/*immunology/metabolism/pathology | 2 | 40.0 |
Up-Regulation/*immunology | 2 | 3.0 |
1-Deoxynojirimycin/pharmacology | 2 | 28.0 |
Carbohydrate Conformation | 5 | 4.0 |
Genes, myc | 3 | 1.0 |
Glycosylation/drug effects | 5 | 15.0 |
Neoplasm Proteins/chemistry/genetics/*physiology | 2 | 22.0 |
Neuraminidase/pharmacology | 5 | 7.0 |
*Protein Processing, Post-Translational/drug effects | 3 | 16.0 |
Tunicamycin/pharmacology | 5 | 6.0 |
Collagen/metabolism | 11 | 4.0 |
Mesoderm/*cytology | 6 | 21.0 |
Mice, Inbred NOD | 5 | 2.0 |
Organ Specificity | 14 | 0.0 |
Osteogenesis | 2 | 8.0 |
Antigens, CD44/*metabolism/physiology | 3 | 100.0 |
Substrate Specificity | 3 | 0.0 |
Antigens, CD44/*analysis/biosynthesis | 4 | 100.0 |
Infant, Newborn | 28 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Cytoplasm/metabolism | 14 | 1.0 |
Endothelium, Vascular/cytology/*metabolism | 2 | 1.0 |
Hyaluronic Acid/*chemistry | 4 | 100.0 |
*Neovascularization, Physiologic | 2 | 1.0 |
Antibodies, Monoclonal/immunology | 64 | 3.0 |
Antigens, Surface/*immunology | 5 | 3.0 |
HT29 Cells | 4 | 2.0 |
DNA, Complementary | 10 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
*Antibodies, Monoclonal | 4 | 1.0 |
Antibody Specificity | 23 | 1.0 |
Cluster Analysis | 2 | 1.0 |
Lymphocytes/cytology/immunology | 2 | 8.0 |
Mitogens/pharmacology | 6 | 2.0 |
Swine/*immunology | 4 | 12.0 |
Collagen/analysis | 3 | 4.0 |
Fibronectins/analysis | 4 | 7.0 |
Image Processing, Computer-Assisted | 6 | 1.0 |
Laminin/physiology | 2 | 25.0 |
Lymph Nodes/*pathology | 2 | 2.0 |
Lymphatic Metastasis/*pathology | 3 | 8.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Hematopoietic Stem Cells/cytology | 4 | 4.0 |
Umbilical Veins | 11 | 2.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 4 | 1.0 |
Antineoplastic Agents, Alkylating/pharmacology | 2 | 7.0 |
Cell Survival/physiology | 3 | 1.0 |
Drug Resistance, Neoplasm | 3 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
src-Family Kinases/*metabolism | 2 | 1.0 |
Hematopoiesis | 12 | 5.0 |
Hematopoietic Stem Cells/*immunology | 8 | 5.0 |
*Cell Adhesion Molecules | 6 | 2.0 |
*Neoplasm Invasiveness | 14 | 18.0 |
Stomach Neoplasms/*pathology | 2 | 4.0 |
Antigens, CD44/chemistry/genetics/*metabolism | 7 | 100.0 |
Melanoma/*metabolism | 4 | 6.0 |
Metalloendopeptidases/antagonists & inhibitors | 2 | 9.0 |
Neoplasm Proteins/chemistry/genetics/*metabolism | 2 | 9.0 |
Pepstatins/pharmacology | 2 | 18.0 |
Phenanthrolines/pharmacology | 2 | 8.0 |
Protease Inhibitors/pharmacology | 7 | 3.0 |
Sequence Deletion | 5 | 0.0 |
Sulfones/pharmacology | 2 | 13.0 |
Cell Line, Transformed | 22 | 1.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 3 | 3.0 |
*Hematopoietic Stem Cell Transplantation | 4 | 1.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Cytoplasm/ultrastructure | 2 | 3.0 |
Receptors, Estrogen/metabolism | 3 | 1.0 |
Receptors, Progesterone/metabolism | 3 | 1.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
HL-60 Cells | 3 | 0.0 |
Hematopoietic Stem Cells/cytology/*metabolism | 3 | 12.0 |
K562 Cells | 3 | 0.0 |
Membrane Glycoproteins/metabolism | 9 | 1.0 |
P-Selectin/metabolism | 2 | 4.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
CD8-Positive T-Lymphocytes/*immunology | 5 | 1.0 |
Epitopes/immunology | 6 | 1.0 |
*Immunotherapy | 2 | 1.0 |
Membrane Glycoproteins/*immunology | 2 | 1.0 |
Peptide Fragments/*immunology | 2 | 1.0 |
Breast Neoplasms/metabolism/*pathology | 2 | 2.0 |
Endothelium/metabolism/pathology | 2 | 28.0 |
Prostatic Neoplasms/metabolism/*pathology | 3 | 4.0 |
RNA Interference | 2 | 0.0 |
Antigens, CD29/metabolism | 10 | 17.0 |
Hyaluronoglucosaminidase/*pharmacology | 2 | 66.0 |
Stomach Neoplasms/metabolism/*pathology | 2 | 6.0 |
Bladder Neoplasms/*genetics/pathology | 2 | 5.0 |
Gestational Age | 9 | 1.0 |
Carcinoma, Squamous Cell/metabolism | 4 | 6.0 |
Culture Media, Conditioned/pharmacology | 3 | 1.0 |
Fibroblast Growth Factor 2/*metabolism | 3 | 5.0 |
Fibroblasts/drug effects/metabolism | 6 | 4.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Colonic Neoplasms/*pathology | 4 | 5.0 |
Forecasting | 2 | 0.0 |
Antigens, Neoplasm/analysis | 8 | 2.0 |
Burkitt Lymphoma/immunology | 3 | 16.0 |
Fluorescent Dyes | 5 | 1.0 |
Immunophenotyping/*methods | 3 | 4.0 |
Frozen Sections | 5 | 6.0 |
Genotype | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 3 | 1.0 |
Fluorescence | 3 | 1.0 |
Lymphocyte Count | 7 | 1.0 |
Reference Values | 31 | 0.0 |
Cell Size/drug effects | 2 | 2.0 |
Plant Proteins/pharmacology | 2 | 18.0 |
Protein Processing, Post-Translational/drug effects | 3 | 2.0 |
Tissue Inhibitor of Metalloproteinase-1/pharmacology | 5 | 50.0 |
Tissue Inhibitor of Metalloproteinase-2/pharmacology | 2 | 50.0 |
Interleukin-8/physiology | 2 | 15.0 |
Menstrual Cycle | 3 | 2.0 |
Antibodies/pharmacology | 9 | 2.0 |
Immunoglobulins, Fab/pharmacology | 3 | 13.0 |
Interleukin-6/*biosynthesis/genetics | 2 | 5.0 |
Neutrophils/*immunology | 3 | 1.0 |
Rabbits | 15 | 0.0 |
Antigens, CD34/genetics/metabolism | 2 | 50.0 |
Intercellular Adhesion Molecule-1/genetics/metabolism | 2 | 11.0 |
Receptors, Cell Surface/genetics/metabolism | 2 | 3.0 |
Lung Neoplasms/*chemistry/pathology | 2 | 11.0 |
Cell Movement/drug effects/physiology | 6 | 10.0 |
Neoplasm Invasiveness/physiopathology | 5 | 29.0 |
Neoplasm Metastasis/physiopathology | 2 | 20.0 |
Adjuvants, Immunologic/administration & dosage | 2 | 11.0 |
Adoptive Transfer | 2 | 2.0 |
Antigens, CD44/*genetics/physiology | 2 | 100.0 |
B-Lymphocytes/pathology | 2 | 2.0 |
Cell Division/drug effects/immunology | 3 | 4.0 |
Injections, Intravenous | 4 | 0.0 |
Leukocyte Count | 11 | 0.0 |
Macrophages/pathology | 3 | 2.0 |
Spleen/cytology/immunology | 2 | 3.0 |
Up-Regulation/drug effects | 6 | 1.0 |
Antigens, CD44/drug effects/*metabolism | 3 | 100.0 |
Extracellular Matrix/drug effects/metabolism | 2 | 11.0 |
Extracellular Matrix Proteins/*biosynthesis | 2 | 22.0 |
Colorectal Neoplasms/*metabolism/mortality/pathology | 2 | 28.0 |
Keratin/metabolism | 3 | 2.0 |
Antigens, Surface/metabolism | 5 | 4.0 |
Urinary Plasminogen Activator/*metabolism | 2 | 5.0 |
*Inflammation | 2 | 5.0 |
Polymorphism, Genetic | 6 | 0.0 |
Arthritis, Rheumatoid/*metabolism/pathology | 3 | 8.0 |
Cartilage, Articular/cytology/metabolism | 2 | 100.0 |
Chondrocytes/*metabolism | 3 | 9.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 8 | 17.0 |
Incidence | 4 | 0.0 |
Prospective Studies | 6 | 0.0 |
*Molecular Diagnostic Techniques | 2 | 33.0 |
Ki-67 Antigen/*metabolism | 2 | 4.0 |
Protein p53/metabolism | 7 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 3 | 0.0 |
Cell Adhesion Molecules/physiology | 16 | 17.0 |
Proteochondroitin Sulfates/analysis | 2 | 40.0 |
Proteoglycans/analysis | 2 | 14.0 |
Wound Healing | 2 | 1.0 |
Antigens, CD44/genetics/*physiology | 8 | 100.0 |
Carcinoma, Non-Small-Cell Lung/*enzymology/pathology | 2 | 40.0 |
Lung Neoplasms/*enzymology/pathology | 2 | 20.0 |
Neoplasm Metastasis/pathology | 2 | 9.0 |
Carcinoma, Squamous Cell/*genetics | 3 | 1.0 |
Keratinocytes/metabolism | 4 | 3.0 |
Mouth Neoplasms/*genetics | 2 | 4.0 |
*RNA Splicing | 11 | 4.0 |
3T3 Cells | 10 | 0.0 |
Carrier Proteins/genetics/*metabolism | 5 | 1.0 |
Hyaluronoglucosaminidase/metabolism | 5 | 55.0 |
Pancreas/metabolism/pathology | 2 | 14.0 |
Recombinant Fusion Proteins/genetics/metabolism | 7 | 0.0 |
Endometrium/*immunology | 2 | 33.0 |
Stromal Cells/immunology | 2 | 8.0 |
Protein Kinases/metabolism | 5 | 1.0 |
Proteins/metabolism | 2 | 0.0 |
*Proto-Oncogene Proteins | 4 | 0.0 |
Receptors, Cell Surface/physiology | 6 | 5.0 |
Liposomes | 2 | 0.0 |
Models, Molecular | 12 | 0.0 |
Sequence Homology, Amino Acid | 17 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 4 | 0.0 |
DNA Primers/genetics | 8 | 0.0 |
Gene Expression/genetics | 2 | 0.0 |
Endothelium, Vascular/metabolism | 9 | 3.0 |
Lymph Nodes/*metabolism | 2 | 11.0 |
Ki-67 Antigen/analysis | 8 | 2.0 |
Neoplasm Recurrence, Local/pathology | 3 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 8 | 4.0 |
Monomeric GTP-Binding Proteins/*analysis | 2 | 33.0 |
Neovascularization, Pathologic/*pathology | 2 | 1.0 |
*Nucleoside-Diphosphate Kinase | 6 | 9.0 |
Transcription Factors/*analysis | 2 | 3.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Adenoma/*genetics | 3 | 3.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Colon/chemistry | 3 | 15.0 |
Colorectal Neoplasms/*genetics | 2 | 0.0 |
Epithelial Cells/cytology | 3 | 4.0 |
Integrin alpha6beta1 | 2 | 10.0 |
Endometrial Neoplasms/*immunology/pathology | 2 | 66.0 |
Carcinoembryonic Antigen/*biosynthesis | 2 | 66.0 |
Neural Cell Adhesion Molecules/*biosynthesis | 2 | 50.0 |
Lymphoma, Non-Hodgkin/*immunology/pathology | 2 | 18.0 |
Proliferating Cell Nuclear Antigen/*biosynthesis | 2 | 3.0 |
Treatment Outcome | 11 | 0.0 |
Heparan Sulfate Proteoglycan/metabolism | 2 | 7.0 |
Proteoglycans/*metabolism | 5 | 7.0 |
Skin/*metabolism | 2 | 1.0 |
Cell Adhesion Molecules/*analysis | 25 | 20.0 |
Hyaluronic Acid | 4 | 80.0 |
Rats, Wistar | 2 | 0.0 |
Stress, Mechanical | 5 | 1.0 |
Tissue Engineering/methods | 2 | 16.0 |
Breast Neoplasms/*immunology/physiopathology | 2 | 50.0 |
Cell Membrane/immunology | 11 | 4.0 |
Cytoplasm/immunology | 3 | 3.0 |
L-Selectin/metabolism | 6 | 18.0 |
Hyaluronic Acid/*biosynthesis | 8 | 40.0 |
Recurrence | 8 | 0.0 |
Stromal Cells/*metabolism | 2 | 5.0 |
Cytokines/biosynthesis | 13 | 2.0 |
Injections, Intradermal | 2 | 4.0 |
Pilot Projects | 4 | 0.0 |
Receptors, Lymphocyte Homing/biosynthesis | 12 | 70.0 |
Prostatic Neoplasms/*genetics | 5 | 2.0 |
Adenocarcinoma/*chemistry/pathology | 4 | 9.0 |
Antigens, CD29/immunology/*physiology | 2 | 100.0 |
Extracellular Matrix Proteins/*physiology | 4 | 19.0 |
Ovarian Neoplasms/*pathology | 2 | 3.0 |
Antibodies, Monoclonal/diagnostic use | 17 | 2.0 |
Antigens, Surface/*analysis | 9 | 4.0 |
Dyes/diagnostic use | 3 | 3.0 |
Platelet Membrane Glycoproteins/analysis | 2 | 2.0 |
Vascular Cell Adhesion Molecule-1/analysis | 3 | 7.0 |
Venules/immunology | 2 | 50.0 |
Colorectal Neoplasms/*immunology/pathology | 4 | 23.0 |
Carbohydrates/metabolism | 3 | 5.0 |
Structure-Activity Relationship | 18 | 0.0 |
Cell Transformation, Neoplastic/metabolism | 3 | 13.0 |
Matrix Metalloproteinases/*metabolism | 3 | 7.0 |
Neoplasms/*enzymology | 2 | 5.0 |
Animals, Newborn | 3 | 0.0 |
Chemotaxis, Leukocyte/*physiology | 2 | 6.0 |
Inflammation | 5 | 1.0 |
Lung/immunology | 2 | 6.0 |
Sheep | 2 | 0.0 |
Chromatography, Affinity | 8 | 1.0 |
Antigens, Neoplasm/genetics/*metabolism | 6 | 30.0 |
Protein Structure, Secondary | 7 | 0.0 |
Cadherins/genetics | 2 | 3.0 |
Glutathione Transferase/genetics | 3 | 1.0 |
Isoenzymes/genetics | 2 | 0.0 |
Receptors, Retinoic Acid/genetics | 3 | 3.0 |
Tumor Suppressor Proteins/genetics | 3 | 4.0 |
Bone Marrow Cells/*metabolism | 4 | 8.0 |
G0 Phase | 2 | 2.0 |
G1 Phase | 3 | 0.0 |
Stem Cells/*cytology | 6 | 6.0 |
U937 Cells | 5 | 1.0 |
Proliferating Cell Nuclear Antigen/analysis | 3 | 1.0 |
Antigens, CD44/immunology/physiology | 3 | 75.0 |
Receptors, Virus/metabolism | 2 | 3.0 |
*Virus Replication | 4 | 1.0 |
Adenylate Cyclase/metabolism | 2 | 1.0 |
Colon/immunology | 3 | 14.0 |
Colonic Neoplasms/*immunology | 2 | 8.0 |
*Lymphocyte Activation | 29 | 2.0 |
T-Lymphocytes/*physiology | 15 | 5.0 |
Epithelial Cells/drug effects/physiology | 2 | 16.0 |
Receptor, Epidermal Growth Factor/metabolism | 3 | 0.0 |
Antigens, CD40/analysis | 3 | 12.0 |
Antigens, CD58/analysis | 3 | 27.0 |
Cell Adhesion Molecules/*analysis/genetics | 2 | 18.0 |
Cell Transformation, Viral | 2 | 0.0 |
Culture Media, Serum-Free | 4 | 1.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Simian virus 40 | 2 | 4.0 |
Cytoplasm/chemistry | 5 | 2.0 |
Extracellular Matrix Proteins/genetics | 3 | 5.0 |
Growth Substances/metabolism | 3 | 2.0 |
Intercellular Adhesion Molecule-1/genetics | 3 | 10.0 |
Carrier Proteins/physiology | 3 | 2.0 |
Cell Fusion | 4 | 1.0 |
Macrophages/*physiology | 3 | 3.0 |
Membrane Glycoproteins/physiology | 6 | 3.0 |
Osteoclasts/*physiology | 2 | 10.0 |
Receptors, Immunologic/physiology | 5 | 4.0 |
Blood Cells/cytology | 2 | 11.0 |
Fetal Blood/*cytology | 4 | 2.0 |
Hematopoietic Stem Cell Transplantation | 5 | 2.0 |
Recombinant Proteins/pharmacology | 8 | 0.0 |
Organ Culture Techniques | 5 | 1.0 |
Proliferating Cell Nuclear Antigen/metabolism | 2 | 0.0 |
Mice, Transgenic/genetics | 2 | 3.0 |
Colorectal Neoplasms/*genetics/*pathology | 4 | 16.0 |
*Gene Amplification | 5 | 1.0 |
Adenocarcinoma/*metabolism | 5 | 5.0 |
Colonic Neoplasms/*metabolism | 4 | 5.0 |
Epithelium/metabolism | 18 | 4.0 |
Bladder Neoplasms/*metabolism/pathology | 4 | 12.0 |
Papilloma/*metabolism/pathology | 3 | 50.0 |
Cytotoxicity, Immunologic/*drug effects | 2 | 2.0 |
Interleukin-2/*pharmacology | 3 | 1.0 |
Antigens, CD44/classification/*metabolism | 2 | 100.0 |
Pancreatic Neoplasms/*metabolism | 2 | 2.0 |
Adenocarcinoma/*metabolism/mortality/pathology | 2 | 13.0 |
Enhancer Elements (Genetics) | 4 | 1.0 |
Drug Resistance | 2 | 0.0 |
Epithelial Cells/cytology/drug effects/metabolism | 3 | 12.0 |
Fetal Blood/cytology | 7 | 3.0 |
Interleukins/biosynthesis | 2 | 4.0 |
Lymphokines/secretion | 2 | 5.0 |
Membrane Glycoproteins/analysis | 5 | 1.0 |
Binding Sites/drug effects/immunology | 2 | 25.0 |
Fixatives | 2 | 2.0 |
Formaldehyde | 5 | 5.0 |
Hyaluronic Acid/immunology/*metabolism | 3 | 100.0 |
Lipopolysaccharides/pharmacology | 11 | 1.0 |
Muromonab-CD3/pharmacology | 2 | 2.0 |
Phytohemagglutinins/pharmacology | 10 | 1.0 |
Polymers | 3 | 2.0 |
T-Lymphocyte Subsets/*immunology | 18 | 3.0 |
Cyclin E/metabolism | 2 | 1.0 |
Antigens, Neoplasm/biosynthesis/*genetics | 3 | 42.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Cell Adhesion/genetics | 5 | 9.0 |
Exons/genetics | 16 | 1.0 |
Ovarian Neoplasms/*genetics | 3 | 0.0 |
Tumor Markers, Biological/biosynthesis/*genetics | 2 | 25.0 |
Epidermal Growth Factor/*pharmacology | 2 | 0.0 |
Cell Division/drug effects/physiology | 6 | 2.0 |
*Epitopes | 2 | 1.0 |
Synovial Membrane/*pathology | 5 | 25.0 |
Glycoproteins/biosynthesis | 4 | 13.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 2 | 2.0 |
China | 2 | 0.0 |
Temperature | 5 | 0.0 |
Cell Membrane/physiology | 4 | 2.0 |
Metalloendopeptidases/antagonists & inhibitors/*metabolism | 2 | 11.0 |
Fluorescent Antibody Technique, Direct | 7 | 6.0 |
Carbon Dioxide | 2 | 22.0 |
Extracellular Matrix/*physiology | 7 | 15.0 |
Antigens, CD44/chemistry/immunology/*metabolism | 2 | 100.0 |
Polysaccharides/chemistry | 2 | 16.0 |
Receptors, Cell Surface/*physiology | 12 | 5.0 |
Antigens, CD44/*chemistry/genetics/*metabolism | 5 | 100.0 |
DNA, Complementary/metabolism | 6 | 0.0 |
Microfilament Proteins/*metabolism | 3 | 4.0 |
Tyrosine/metabolism | 3 | 0.0 |
Antigens, CD44/drug effects/*physiology | 2 | 100.0 |
Breast Neoplasms | 5 | 1.0 |
Carcinoma | 3 | 8.0 |
Culture Media, Conditioned | 4 | 1.0 |
Epithelial Cells/cytology/physiology | 2 | 6.0 |
Protein Isoforms/physiology | 2 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 5 | 1.0 |
Colorectal Neoplasms/*metabolism | 2 | 4.0 |
Hepatocyte Growth Factor/metabolism | 3 | 5.0 |
Proto-Oncogene Protein c-met/*metabolism | 4 | 6.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
*Receptor Aggregation | 2 | 15.0 |
Interleukin-2/secretion | 2 | 2.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Receptors, Antigen, T-Cell/immunology | 5 | 2.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Endothelium, Vascular/physiology | 2 | 3.0 |
Gene Dosage | 2 | 0.0 |
Stomach Neoplasms/*genetics/pathology | 2 | 4.0 |
Ovary/immunology/metabolism | 2 | 66.0 |
Antigens, CD44/analysis/*biosynthesis/genetics | 3 | 100.0 |
Genes, bcl-2 | 2 | 1.0 |
Chemotaxis | 4 | 2.0 |
Cytoskeleton/physiology | 9 | 11.0 |
Interleukin-8/pharmacology | 3 | 6.0 |
Microscopy, Video | 4 | 5.0 |
Paraffin Embedding | 7 | 2.0 |
Tumor Markers, Biological/*blood | 8 | 1.0 |
Cell Differentiation/drug effects/immunology | 3 | 4.0 |
Epitopes, T-Lymphocyte/immunology | 2 | 2.0 |
Killer Cells, Natural/drug effects/*immunology | 2 | 5.0 |
*Lymphocyte Activation/drug effects | 3 | 2.0 |
Mice, Inbred DBA | 3 | 0.0 |
Antigens, CD44/genetics/physiology | 2 | 100.0 |
Burkitt Lymphoma | 3 | 3.0 |
Cytokines/*physiology | 5 | 2.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
*Bacterial Adhesion/drug effects | 2 | 50.0 |
Epithelial Cells/metabolism | 5 | 1.0 |
Gene Library | 7 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 6 | 3.0 |
Granulocytes/metabolism | 4 | 10.0 |
Models, Genetic | 4 | 0.0 |
Neutrophils/*metabolism | 4 | 2.0 |
Proteins/*genetics | 2 | 0.0 |
Antigens, CD/*blood | 3 | 1.0 |
Antigens, CD18/blood | 2 | 25.0 |
Antigens, CD44/blood | 7 | 87.0 |
Cell Adhesion Molecules/*blood | 5 | 8.0 |
Hydrocortisone/blood | 2 | 0.0 |
Integrin alpha4 | 9 | 22.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
Oncogenes/genetics | 3 | 4.0 |
Interleukin-8/genetics | 2 | 3.0 |
Cell Communication | 8 | 2.0 |
Models, Neurological | 2 | 1.0 |
B-Lymphocytes/*physiology | 7 | 4.0 |
Tonsil/cytology | 8 | 9.0 |
Hematopoiesis/*physiology | 2 | 2.0 |
*Hematopoietic Stem Cell Mobilization | 2 | 3.0 |
Hematopoietic Stem Cells/*physiology | 3 | 2.0 |
Antigens, Ly/metabolism | 2 | 40.0 |
*Immunologic Memory | 8 | 5.0 |
Antigens, CD/*biosynthesis | 15 | 7.0 |
Chondroitin ABC Lyase/pharmacology | 2 | 25.0 |
Proteochondroitin Sulfates/*metabolism | 4 | 40.0 |
*Gene Silencing | 2 | 1.0 |
Lymphatic Metastasis/immunology | 2 | 33.0 |
Antigens, CD44/*biosynthesis/physiology | 2 | 100.0 |
Lymphocytes/metabolism | 4 | 1.0 |
Carcinoma, Squamous Cell/genetics/metabolism/*pathology | 2 | 25.0 |
Mesenchymal Stem Cells/*cytology | 2 | 25.0 |
Receptors, Cell Surface/metabolism | 13 | 3.0 |
Arthritis, Rheumatoid/*pathology | 2 | 10.0 |
Chondrocytes/cytology | 2 | 16.0 |
Extracellular Matrix/physiology | 13 | 14.0 |
Bone Marrow Cells/immunology/*pathology | 2 | 22.0 |
Interleukin-6/metabolism | 5 | 2.0 |
Extracellular Matrix Proteins/*analysis | 3 | 15.0 |
Chondroitin Sulfates/metabolism | 9 | 30.0 |
Lung Neoplasms/metabolism/secondary | 2 | 33.0 |
Protein Isoforms/biosynthesis | 3 | 16.0 |
Cell Adhesion/immunology | 23 | 13.0 |
Chemokines/immunology | 2 | 12.0 |
Cytokines/immunology | 4 | 2.0 |
Macrophage Activation | 3 | 1.0 |
Monocytes/immunology/metabolism | 2 | 4.0 |
Cathepsin D/analysis | 2 | 5.0 |
Epithelium/pathology | 5 | 3.0 |
Laryngeal Neoplasms/chemistry/*pathology | 2 | 50.0 |
Precancerous Conditions/chemistry/*pathology | 2 | 28.0 |
Bone Marrow Cells/metabolism | 2 | 2.0 |
Exons/*genetics | 7 | 2.0 |
Neoplasms/*genetics/*pathology | 2 | 25.0 |
*Antigens, CD44 | 2 | 9.0 |
Cell Adhesion Molecules | 8 | 15.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 2 | 2.0 |
Hyperplasia | 7 | 1.0 |
Amino Acid Motifs | 2 | 0.0 |
Antigens, CD44/chemistry | 3 | 100.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Oligosaccharides/metabolism | 3 | 6.0 |
Sequence Alignment | 11 | 0.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 4 | 3.0 |
Cell Movement/*drug effects | 3 | 3.0 |
Lymphocyte Activation/*drug effects | 7 | 2.0 |
B-Lymphocytes/immunology | 8 | 1.0 |
*Flow Cytometry | 3 | 1.0 |
Killer Cells, Natural/immunology | 6 | 1.0 |
Macrophages/immunology | 4 | 1.0 |
Rats, Inbred Lew | 3 | 1.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 2 | 5.0 |
Spleen/immunology | 4 | 2.0 |
Lung Neoplasms | 3 | 2.0 |
Intestinal Mucosa/*immunology | 4 | 4.0 |
Neutrophils/physiology | 3 | 2.0 |
Killer Cells, Natural/*immunology | 12 | 2.0 |
Bone Marrow/pathology | 12 | 3.0 |
Hematopoietic Stem Cells/pathology | 2 | 5.0 |
Hyaluronic Acid/chemistry/metabolism/*pharmacology | 2 | 100.0 |
Antigens, CD/*analysis | 29 | 3.0 |
Glial Fibrillary Acidic Protein/metabolism | 2 | 0.0 |
Antigens, CD/biosynthesis | 11 | 3.0 |
Mutation/genetics | 2 | 0.0 |
Protein Biosynthesis | 10 | 0.0 |
*Proteins | 2 | 0.0 |
Transcription Factor AP-1/metabolism | 4 | 1.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
Glycoproteins/genetics/*metabolism | 2 | 5.0 |
Insulin-Like Growth Factor I/pharmacology | 2 | 1.0 |
Culture Techniques | 4 | 0.0 |
Interleukin-1/*pharmacology | 7 | 1.0 |
Proteoglycans/genetics/metabolism | 2 | 28.0 |
Collagen/*metabolism | 3 | 1.0 |
Hyaluronic Acid/metabolism/pharmacology | 7 | 87.0 |
Basement Membrane/*cytology | 2 | 100.0 |
Collagen | 11 | 6.0 |
Dogs | 12 | 1.0 |
Bone Marrow/*pathology | 7 | 4.0 |
Integrin alpha4beta1 | 21 | 25.0 |
Multiple Myeloma/*pathology | 8 | 13.0 |
Receptors, Lymphocyte Homing/immunology/*physiology | 4 | 80.0 |
*Cell Adhesion | 25 | 15.0 |
Cell Adhesion Molecules/biosynthesis/*physiology | 4 | 44.0 |
Neoplasm Metastasis/*physiopathology | 8 | 26.0 |
Peritoneal Neoplasms/secondary | 2 | 14.0 |
Antigens, CD11/metabolism | 6 | 31.0 |
Calcium/metabolism | 9 | 0.0 |
Endothelium, Vascular/cytology/*physiology | 4 | 6.0 |
Neutrophils/drug effects/*metabolism/physiology | 2 | 33.0 |
Wound Healing/*physiology | 3 | 4.0 |
*Drug Delivery Systems | 2 | 6.0 |
Drug Design | 2 | 0.0 |
Permeability | 3 | 1.0 |
Intercellular Adhesion Molecule-1/*analysis | 2 | 10.0 |
Lung Neoplasms/pathology/*secondary | 2 | 33.0 |
Neoplasm Metastasis/*pathology | 6 | 33.0 |
Pancreatic Neoplasms/*pathology | 2 | 5.0 |
Cell Membrane/*physiology | 3 | 15.0 |
Endothelium, Vascular/cytology/drug effects/*physiology | 2 | 4.0 |
Skin/blood supply | 3 | 4.0 |
Antigens, CD/*immunology | 13 | 2.0 |
Antigens, CD44/immunology | 9 | 90.0 |
Antigens, CD45/immunology | 2 | 3.0 |
Intercellular Adhesion Molecule-1/immunology | 3 | 7.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Osteoblasts/*immunology | 2 | 66.0 |
Fibroblasts/*physiology | 2 | 3.0 |
Receptors, Fibroblast Growth Factor/metabolism | 2 | 4.0 |
Receptors, Platelet-Derived Growth Factor/metabolism | 2 | 4.0 |
Antigens, Surface/analysis | 18 | 4.0 |
Cell Survival/drug effects/physiology | 2 | 2.0 |
Leukemia, Myelocytic, Acute | 3 | 11.0 |
Leukemia, T-Cell | 2 | 5.0 |
Osmolar Concentration | 2 | 0.0 |
Interferon Type II/*pharmacology | 6 | 1.0 |
Tritium | 2 | 0.0 |
Antigens, CD44/*analysis/physiology | 3 | 100.0 |
Placenta/*cytology | 3 | 17.0 |
*Disease Models, Animal | 2 | 0.0 |
*Tumor Cells, Cultured | 3 | 4.0 |
Staining and Labeling | 17 | 2.0 |
*Helicobacter pylori | 3 | 2.0 |
Endothelial Growth Factors/*metabolism | 2 | 0.0 |
Liver Neoplasms/*secondary | 2 | 10.0 |
Lymphokines/*metabolism | 2 | 0.0 |
Glycosaminoglycans/chemistry | 2 | 33.0 |
*Cell Transformation, Neoplastic | 4 | 0.0 |
Membrane Proteins/metabolism | 9 | 1.0 |
Protein Processing, Post-Translational | 8 | 1.0 |
Proto-Oncogene Protein c-met/metabolism | 2 | 2.0 |
Proto-Oncogene Proteins/metabolism | 5 | 0.0 |
Gene Expression/physiology | 2 | 0.0 |
Chemotherapy, Adjuvant | 4 | 1.0 |
CD4-Positive T-Lymphocytes/immunology | 14 | 1.0 |
CD8-Positive T-Lymphocytes/immunology | 5 | 1.0 |
Cross Reactions | 4 | 0.0 |
Lymphocyte Activation/immunology | 11 | 2.0 |
Carcinoma/*metabolism | 3 | 3.0 |
*Protein Processing, Post-Translational | 4 | 1.0 |
Preoperative Care | 2 | 1.0 |
Lymph Nodes/chemistry/*pathology | 2 | 33.0 |
Aspirin/pharmacology | 2 | 3.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Methotrexate/pharmacology | 3 | 3.0 |
Cell Size/physiology | 2 | 5.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Cell Membrane/chemistry | 5 | 3.0 |
Immunoassay | 2 | 0.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 5 | 1.0 |
Recombinant Proteins/blood | 2 | 13.0 |
Carcinoma, Squamous Cell/*chemistry/mortality/pathology | 2 | 25.0 |
Lymph Nodes/chemistry | 3 | 13.0 |
Registries | 2 | 0.0 |
Epidermis/metabolism | 2 | 5.0 |
Antigens, Neoplasm/*blood | 5 | 11.0 |
Remission Induction | 2 | 0.0 |
Antigens, CD/analysis/*physiology | 3 | 10.0 |
Endothelium, Vascular/cytology/*immunology | 5 | 15.0 |
Lymphocytes/cytology/*immunology | 3 | 18.0 |
Antigens, CD44/metabolism/*physiology | 4 | 100.0 |
Antigens, CD3/analysis | 3 | 1.0 |
Antigens, CD80/analysis | 2 | 4.0 |
Interleukin-2/analysis | 2 | 4.0 |
Heparan Sulfate Proteoglycan/*metabolism | 2 | 12.0 |
Interleukin-1/metabolism | 3 | 1.0 |
Monocytes/cytology/immunology | 2 | 5.0 |
Synovial Membrane/immunology/pathology | 2 | 18.0 |
Colonic Neoplasms/genetics/*pathology | 2 | 13.0 |
Genetic Markers | 5 | 0.0 |
Endothelium, Vascular/*metabolism | 3 | 1.0 |
Inflammation/metabolism | 4 | 5.0 |
Lymphocyte Function-Associated Antigen-1/*metabolism | 3 | 11.0 |
Antigens, CD44/chemistry/metabolism | 2 | 100.0 |
Chondroitin ABC Lyase/metabolism | 2 | 40.0 |
Proteoglycans/chemistry/metabolism | 2 | 40.0 |
Cathepsin D/metabolism | 2 | 5.0 |
Cell Movement/immunology | 8 | 8.0 |
Neoplasms/immunology | 4 | 7.0 |
Signal Transduction/immunology | 3 | 0.0 |
Terminology | 4 | 2.0 |
Liver Neoplasms/pathology/*secondary | 2 | 28.0 |
Cell Separation/*methods | 5 | 3.0 |
Edetic Acid/pharmacology | 4 | 2.0 |
Flow Cytometry/*methods | 3 | 1.0 |
Indicators and Reagents | 2 | 0.0 |
Tonsil/*cytology/immunology | 2 | 25.0 |
Variation (Genetics) | 31 | 1.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
Mouth Neoplasms/*metabolism | 2 | 8.0 |
Neoplasm Staging/methods | 2 | 6.0 |
RNA Splicing | 14 | 2.0 |
Brain/pathology | 3 | 0.0 |
Endothelium, Vascular/chemistry | 4 | 6.0 |
Melanoma/*metabolism/pathology | 2 | 5.0 |
Epithelium/immunology | 13 | 9.0 |
Lymphocytes/immunology | 9 | 2.0 |
Protein p53/*metabolism | 5 | 0.0 |
Glial Fibrillary Acidic Protein/analysis | 4 | 2.0 |
Cell Communication/physiology | 7 | 7.0 |
Inflammation/*immunology | 3 | 5.0 |
Leukocytes/*physiology | 2 | 3.0 |
Selectins/metabolism | 2 | 25.0 |
Sulfates/*metabolism | 3 | 9.0 |
Gene Expression Regulation, Neoplastic/immunology | 2 | 7.0 |
Protein Kinase C/*physiology | 3 | 3.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 5 | 5.0 |
Uterine Neoplasms/*metabolism/pathology | 3 | 20.0 |
Endometrial Neoplasms/*pathology | 2 | 18.0 |
Colon/metabolism | 2 | 1.0 |
Ovarian Neoplasms/*chemistry/mortality/pathology | 2 | 100.0 |
Bone Morphogenetic Proteins/*pharmacology | 2 | 3.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/genetics | 3 | 7.0 |
Hyaluronic Acid/biosynthesis | 2 | 20.0 |
Proteoglycans/*genetics | 2 | 3.0 |
Antigens, CD44/*biosynthesis/*genetics | 5 | 100.0 |
Glycoproteins/biosynthesis/genetics | 2 | 10.0 |
DNA/genetics | 7 | 0.0 |
*DNA, Recombinant | 2 | 5.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
*Genes, p53 | 2 | 0.0 |
Tumor Virus Infections/*immunology | 2 | 22.0 |
Arthritis, Rheumatoid/*metabolism | 2 | 3.0 |
Synovial Membrane/*metabolism/pathology | 2 | 9.0 |
Cytokines/physiology | 7 | 3.0 |
Extracellular Matrix Proteins/physiology | 4 | 28.0 |
Hyaluronic Acid/pharmacology/physiology | 2 | 100.0 |
Neoplasm Proteins/physiology | 3 | 4.0 |
Bronchoalveolar Lavage Fluid/cytology | 3 | 2.0 |
Eosinophils/cytology | 2 | 14.0 |
*Phenotype | 2 | 0.0 |
Receptors, Cell Surface/genetics | 3 | 2.0 |
*Fetal Blood | 2 | 4.0 |
Immunoglobulin G/immunology | 3 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Regression Analysis | 7 | 0.0 |
Etoposide/pharmacology | 2 | 1.0 |
Cell Cycle Proteins/physiology | 2 | 5.0 |
Leiomyosarcoma/*chemistry/genetics | 2 | 100.0 |
Monosaccharide Transport Proteins/analysis | 2 | 33.0 |
Uterine Neoplasms/*chemistry/genetics | 2 | 100.0 |
Brain Neoplasms/*enzymology/pathology | 2 | 25.0 |
DNA, Antisense | 3 | 8.0 |
Glioma/*enzymology/pathology | 2 | 66.0 |
Isoenzymes/*physiology | 2 | 6.0 |
Laminin | 7 | 7.0 |
Proteoglycans | 7 | 8.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Receptor, erbB-2/analysis | 3 | 3.0 |
Adenocarcinoma/*immunology | 4 | 10.0 |
Antigens, CD/genetics | 6 | 4.0 |
Cytokines/*pharmacology | 10 | 2.0 |
Interferon-gamma, Recombinant/pharmacology | 4 | 2.0 |
Interleukin-2/pharmacology | 8 | 1.0 |
Keratinocytes/cytology | 2 | 5.0 |
Mesoderm/cytology | 2 | 5.0 |
Sebaceous Glands/metabolism | 2 | 50.0 |
Sweat Glands/metabolism | 2 | 28.0 |
B-Lymphocytes/*immunology | 17 | 2.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Immunoglobulin D/analysis | 3 | 13.0 |
Th2 Cells/immunology | 3 | 1.0 |
Antigens, CD95/immunology | 2 | 3.0 |
Ultraviolet Rays | 3 | 0.0 |
Cytoskeleton | 3 | 10.0 |
Neurofibromin 2 | 2 | 2.0 |
rac1 GTP-Binding Protein/genetics/*metabolism | 2 | 6.0 |
Liver Neoplasms/immunology/pathology/*secondary | 2 | 66.0 |
Alternative Splicing/genetics | 6 | 3.0 |
Neoplasm Metastasis/genetics | 2 | 4.0 |
Arthritis, Rheumatoid/metabolism | 3 | 9.0 |
Cell Adhesion Molecules/blood/*metabolism | 2 | 50.0 |
Osteoarthritis/metabolism | 2 | 5.0 |
Antigens, CD34/immunology | 3 | 5.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 3 | 5.0 |
Bone Marrow/immunology | 4 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Cytarabine/administration & dosage | 2 | 2.0 |
Tumor Markers, Biological/blood | 4 | 2.0 |
Administration, Oral | 5 | 0.0 |
Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage | 2 | 11.0 |
T-Lymphocytes, Cytotoxic/immunology | 3 | 0.0 |
Interferon-alpha/pharmacology | 2 | 2.0 |
Eosinophils/immunology | 2 | 3.0 |
Granulocytes/*immunology | 2 | 5.0 |
Integrins/*biosynthesis | 4 | 23.0 |
Metyrapone/pharmacology | 2 | 15.0 |
Prednisolone/*pharmacology | 2 | 22.0 |
Antigens, CD34/*metabolism | 4 | 3.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 4 | 3.0 |
Lymph Nodes/immunology | 6 | 6.0 |
Antigens, CD14/metabolism | 3 | 2.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Stromal Cells/metabolism | 7 | 7.0 |
T-Lymphocytes/metabolism | 4 | 1.0 |
Membrane Proteins/*metabolism | 9 | 1.0 |
*Antigens, CD3 | 3 | 15.0 |
T-Lymphocytes/cytology/*metabolism | 2 | 6.0 |
Carcinoma, Squamous Cell/metabolism/pathology | 2 | 5.0 |
Keratosis/metabolism/pathology | 2 | 50.0 |
Ki-67 Antigen/*biosynthesis | 2 | 7.0 |
Protein p53/*biosynthesis | 3 | 2.0 |
Prostatic Neoplasms/*chemistry/pathology | 2 | 9.0 |
Carcinoma, Squamous Cell/*metabolism/pathology/secondary | 2 | 40.0 |
Neovascularization, Pathologic | 2 | 0.0 |
Glucuronosyltransferase/metabolism | 3 | 11.0 |
Hydrolysis | 2 | 0.0 |
Intestinal Mucosa/*immunology/pathology | 5 | 19.0 |
Monocytes/immunology | 5 | 1.0 |
Alzheimer Disease/*pathology | 2 | 3.0 |
Glial Fibrillary Acidic Protein/immunology/metabolism | 2 | 28.0 |
Blood Group Antigens/*immunology | 3 | 9.0 |
Erythrocytes/*immunology | 7 | 3.0 |
Hybridomas/*immunology | 2 | 6.0 |
Isoantigens/immunology | 2 | 2.0 |
Macaca mulatta | 2 | 0.0 |
Species Specificity | 9 | 0.0 |
Extracellular Matrix Proteins/analysis | 2 | 11.0 |
Receptor, Epidermal Growth Factor/analysis | 2 | 1.0 |
Receptors, Progesterone/analysis | 3 | 1.0 |
Retinoblastoma Protein/analysis | 2 | 5.0 |
Subcellular Fractions/chemistry | 2 | 3.0 |
Estradiol/pharmacology | 2 | 0.0 |
Cell Culture Techniques/*methods | 5 | 5.0 |
Organoids | 2 | 33.0 |
Biological Markers/blood | 5 | 0.0 |
Calcium/*metabolism | 4 | 0.0 |
GTP-Binding Proteins/*metabolism | 2 | 0.0 |
Glioblastoma/metabolism | 2 | 8.0 |
*Diagnostic Techniques and Procedures | 2 | 66.0 |
Genome | 2 | 0.0 |
Molecular Biology/*methods | 2 | 8.0 |
*Molecular Probes/diagnostic use | 2 | 100.0 |
Interleukin-2/*biosynthesis | 2 | 1.0 |
Transplantation, Homologous | 3 | 0.0 |
Hyaluronic Acid/*immunology | 3 | 100.0 |
Protein Isoforms/analysis/genetics | 3 | 23.0 |
Antigens, CD44/biosynthesis/blood | 2 | 100.0 |
HIV-1/*immunology | 4 | 0.0 |
L-Selectin/biosynthesis/blood | 2 | 66.0 |
Neoplasm Metastasis/*genetics | 7 | 11.0 |
Stomach Neoplasms/*genetics | 7 | 6.0 |
Chromatography, Gel | 2 | 0.0 |
Antigens, CD28/*metabolism | 2 | 1.0 |
Bone Marrow Cells/*physiology | 3 | 16.0 |
Antigens, CD/immunology | 12 | 2.0 |
Thymus Gland/cytology/*immunology | 2 | 6.0 |
Adenoviruses, Human/*genetics | 2 | 1.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 5 | 1.0 |
Ankyrins/*metabolism | 2 | 33.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 2 | 0.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Immunomagnetic Separation | 2 | 1.0 |
Lymphocyte Culture Test, Mixed | 5 | 0.0 |
Antibodies, Blocking/pharmacology | 4 | 4.0 |
Protein Binding/genetics/immunology | 2 | 2.0 |
Integrins/biosynthesis | 4 | 16.0 |
T-Lymphocytes/*immunology/metabolism | 5 | 3.0 |
Antigens, CD/analysis/genetics | 2 | 6.0 |
Flow Cytometry/methods | 9 | 3.0 |
Muscle, Smooth/*metabolism | 2 | 8.0 |
B-Lymphocytes/*immunology/*metabolism | 2 | 11.0 |
Receptor Cross-Talk | 2 | 5.0 |
Gene Expression Regulation, Neoplastic/*physiology | 2 | 1.0 |
Antigens, Neoplasm/*analysis | 13 | 3.0 |
Antigens, CD44/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Antigens, CD/genetics/metabolism | 2 | 3.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
*Cytoskeletal Proteins | 5 | 4.0 |
Membrane Proteins/genetics/*metabolism | 3 | 1.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Cell Membrane | 2 | 3.0 |
Cytochalasin D/pharmacology | 5 | 6.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Chondroitin Sulfates/pharmacology | 3 | 25.0 |
Muscle, Smooth, Vascular/*metabolism | 2 | 4.0 |
Surface Properties | 3 | 1.0 |
Liver Neoplasms/metabolism/secondary | 2 | 14.0 |
Precancerous Conditions/metabolism/pathology | 3 | 20.0 |
Monocytes/*immunology | 11 | 2.0 |
Antigens, CD15/metabolism | 4 | 30.0 |
Respiratory Burst | 2 | 3.0 |
Antigens, CD44/*analysis/immunology | 3 | 100.0 |
Epithelium | 4 | 6.0 |
Receptors, Fibronectin/physiology | 3 | 37.0 |
Antigens, Neoplasm/metabolism | 5 | 7.0 |
Paranasal Sinus Neoplasms/*metabolism/pathology | 2 | 100.0 |
Adenocarcinoma/metabolism | 2 | 2.0 |
Cervical Intraepithelial Neoplasia/metabolism | 2 | 40.0 |
Cervix Uteri/metabolism | 2 | 11.0 |
*Monomeric GTP-Binding Proteins | 2 | 4.0 |
Up-Regulation/physiology | 2 | 1.0 |
Antigens, Surface/*genetics | 4 | 6.0 |
Gelatinases/*metabolism | 2 | 8.0 |
Keratinocytes/immunology | 4 | 16.0 |
Skin/*immunology | 4 | 3.0 |
Hyaluronic Acid/physiology | 9 | 90.0 |
Life Tables | 3 | 1.0 |
B-Lymphocytes/*metabolism | 7 | 3.0 |
Plasma Cells/*metabolism | 3 | 25.0 |
Adenocarcinoma/*genetics/pathology/secondary | 2 | 50.0 |
*Transcription, Genetic | 9 | 0.0 |
Antigens, CD44/*blood/immunology | 2 | 100.0 |
Lymphoma, Non-Hodgkin/blood/*immunology/physiopathology | 2 | 100.0 |
Antigens, CD/*physiology | 12 | 3.0 |
Antigens, CD29/*immunology | 4 | 57.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Ovarian Neoplasms/*immunology | 4 | 12.0 |
Breast Neoplasms/*chemistry/mortality/pathology | 3 | 15.0 |
Cell Adhesion Molecules/*immunology | 11 | 21.0 |
Swine | 6 | 0.0 |
Transplantation, Heterologous/*immunology | 3 | 5.0 |
Cell Adhesion Molecules/immunology/*metabolism | 4 | 40.0 |
Biocompatible Materials | 2 | 3.0 |
Brain Neoplasms/*metabolism | 3 | 4.0 |
Molecular Probes | 2 | 3.0 |
Cell Movement/*immunology | 10 | 14.0 |
Leukemia, B-Cell, Chronic/*immunology | 2 | 4.0 |
RNA, Neoplasm/genetics/metabolism | 3 | 2.0 |
Down-Regulation/immunology | 3 | 3.0 |
Enzyme Activation/immunology | 4 | 3.0 |
Interleukin-4/*pharmacology | 3 | 1.0 |
Monocytes/drug effects/*metabolism | 4 | 3.0 |
Actins/analysis | 2 | 1.0 |
Dyes | 6 | 5.0 |
Cell Adhesion Molecules, Neuronal/*physiology | 2 | 28.0 |
Integrins/physiology | 10 | 14.0 |
Cell Adhesion Molecules/immunology | 7 | 10.0 |
Leukocytes/*immunology | 4 | 2.0 |
Antineoplastic Agents/*pharmacology | 6 | 0.0 |
Butyrates/*pharmacology | 2 | 4.0 |
Colorectal Neoplasms/*immunology | 4 | 15.0 |
Antigens, CD44/*biosynthesis/immunology | 4 | 100.0 |
Endothelium, Vascular/cytology/immunology/metabolism | 2 | 20.0 |
*Immediate-Early Proteins | 6 | 2.0 |
Promoter Regions (Genetics)/immunology | 2 | 2.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Monocytes/drug effects/*immunology | 4 | 5.0 |
Neoplasm Circulating Cells/*metabolism | 2 | 22.0 |
Antigens, CD19/analysis | 2 | 2.0 |
Bone Marrow Cells | 17 | 3.0 |
Neprilysin/analysis | 3 | 5.0 |
Stromal Cells/cytology | 4 | 8.0 |
Fibronectins | 2 | 9.0 |
*Gene Expression Regulation | 7 | 0.0 |
Hematopoietic Stem Cells/drug effects/*metabolism | 2 | 10.0 |
Interleukin-3/pharmacology | 8 | 2.0 |
Interleukin-6/pharmacology | 4 | 1.0 |
Stem Cell Factor/pharmacology | 6 | 4.0 |
Cations, Divalent | 2 | 2.0 |
Immunoglobulins/metabolism | 4 | 3.0 |
Postoperative Care | 2 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Cytoplasm | 2 | 3.0 |
Mutagenesis | 3 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Receptors, IgG/*metabolism | 2 | 3.0 |
Leukemia/immunology/*pathology | 2 | 25.0 |
Cytoskeletal Proteins/analysis | 2 | 4.0 |
Antigens, CD44/chemistry/*metabolism | 7 | 100.0 |
Hepatocyte Growth Factor/*pharmacology | 2 | 1.0 |
Stomach Neoplasms/*chemistry/pathology | 3 | 21.0 |
Alternative Splicing/*physiology | 2 | 11.0 |
Nerve Tissue Proteins/*metabolism | 3 | 1.0 |
RNA Precursors/metabolism | 2 | 6.0 |
RNA-Binding Proteins/*metabolism | 2 | 2.0 |
Tyrosine/*metabolism | 3 | 0.0 |
Chromosome Deletion | 3 | 0.0 |
DNA/analysis | 5 | 0.0 |
Antigens, CD/genetics/*metabolism | 2 | 2.0 |
Antigens, CD4/*metabolism | 2 | 0.0 |
Intercellular Adhesion Molecule-1/*metabolism | 6 | 10.0 |
*Membrane Glycoproteins | 6 | 0.0 |
Receptors, Lymphocyte Homing | 27 | 75.0 |
Skin/*immunology/pathology | 2 | 10.0 |
Chemotaxis, Leukocyte/*drug effects | 2 | 3.0 |
Transforming Growth Factor beta/*pharmacology | 6 | 1.0 |
Adenoma/metabolism/pathology | 4 | 14.0 |
Carcinoma/metabolism/pathology | 2 | 11.0 |
Intestinal Mucosa/metabolism/pathology | 3 | 10.0 |
Mice, Mutant Strains | 4 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
*Zebrafish Proteins | 2 | 0.0 |
Mouth Mucosa/immunology/pathology | 2 | 20.0 |
Antigens, Surface/physiology | 2 | 5.0 |
T-Lymphocytes/physiology | 3 | 2.0 |
Protein Isoforms/immunology | 2 | 28.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Prostatic Neoplasms/genetics/*metabolism | 2 | 7.0 |
Collagenases/metabolism | 2 | 5.0 |
Gelatinase A | 4 | 5.0 |
Gelatinase B | 3 | 3.0 |
Gelatinases/metabolism | 2 | 6.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Metalloendopeptidases/*metabolism | 4 | 4.0 |
Breast Neoplasms/diagnosis/*metabolism/mortality | 2 | 40.0 |
Antigens, CD34/metabolism | 2 | 0.0 |
Antigens, Thy-1/metabolism | 2 | 40.0 |
Proto-Oncogene Protein c-kit/metabolism | 3 | 6.0 |
Receptors, Antigen, T-Cell/metabolism | 4 | 2.0 |
Mouth Neoplasms/*pathology | 2 | 8.0 |
Antigens, CD44/analysis/*genetics | 7 | 100.0 |
Colorectal Neoplasms/genetics/*immunology/pathology | 2 | 66.0 |
Molecular Biology | 3 | 1.0 |
Neoplasms/metabolism | 2 | 2.0 |
*Variation (Genetics)/genetics | 2 | 50.0 |
Colorectal Neoplasms/genetics/*metabolism | 2 | 9.0 |
Antigens, CD58/metabolism | 3 | 18.0 |
Transfection/genetics | 2 | 1.0 |
Apoptosis/*immunology | 4 | 2.0 |
Interphase/immunology | 2 | 4.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 11 | 25.0 |
Receptors, Lymphocyte Homing/*physiology | 25 | 80.0 |
Forskolin/pharmacology | 2 | 0.0 |
Arteriosclerosis/*pathology | 2 | 7.0 |
Endothelium, Vascular/*pathology | 2 | 3.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Ribonucleoproteins/*metabolism | 2 | 4.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Colon/*immunology | 3 | 13.0 |
Isomerism | 21 | 8.0 |
B-Lymphocytes/*cytology/immunology | 2 | 6.0 |
Cell Communication/*immunology | 2 | 4.0 |
Mice, Inbred CBA | 5 | 1.0 |
Antigens, CD56/metabolism | 2 | 7.0 |
Tumor Cells, Cultured/drug effects | 6 | 1.0 |
Valproic Acid/*pharmacology | 2 | 10.0 |
Protein-Tyrosine Kinase/*metabolism | 3 | 0.0 |
Adenoma/*metabolism/pathology | 3 | 8.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
Carcinoma/*metabolism/pathology | 3 | 4.0 |
Colorectal Neoplasms/*metabolism/pathology | 4 | 8.0 |
Cell Adhesion Molecules/*genetics/metabolism | 2 | 16.0 |
Evaluation Studies | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 2 | 3.0 |
Brain Neoplasms/metabolism/*pathology | 2 | 8.0 |
Cell Adhesion Molecules/*physiology | 34 | 30.0 |
Antigens, CD44/*genetics/*metabolism | 6 | 100.0 |
Hematopoietic System | 2 | 50.0 |
Breast Neoplasms/pathology | 2 | 1.0 |
Colonic Neoplasms/pathology | 2 | 3.0 |
Carrier Proteins/*biosynthesis | 5 | 9.0 |
*Renal Dialysis | 2 | 0.0 |
Keratin/analysis | 5 | 2.0 |
Antigens, CD44/genetics/*immunology | 2 | 100.0 |
Multiple Myeloma/*immunology/pathology | 2 | 11.0 |
Antigens, CD44/*chemistry/*immunology | 2 | 100.0 |
Membrane Proteins/*immunology | 2 | 3.0 |
Cell Compartmentation/*immunology | 2 | 40.0 |
Lymphocytes/*cytology | 3 | 9.0 |
Germinal Center/*cytology/*immunology | 2 | 100.0 |
Plastics | 2 | 6.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Melanocytes/chemistry | 3 | 33.0 |
Nevus/chemistry | 2 | 50.0 |
Recombinant Proteins/biosynthesis/metabolism | 3 | 1.0 |
Lymphatic Metastasis/genetics/immunology | 2 | 100.0 |
Dendritic Cells/*immunology | 7 | 2.0 |
Fibroblasts/immunology | 6 | 8.0 |
Stromal Cells/*immunology | 3 | 42.0 |
Arthritis, Rheumatoid/*immunology | 10 | 4.0 |
Synovial Membrane/*immunology | 3 | 8.0 |
Antibodies, Monoclonal/*analysis | 2 | 4.0 |
CD4-CD8 Ratio | 3 | 0.0 |
Epithelium/chemistry | 6 | 5.0 |
*Integrin beta Chains | 4 | 25.0 |
Integrins/*analysis | 10 | 41.0 |
Immunosuppressive Agents/*pharmacology | 3 | 1.0 |
Protein Biosynthesis/genetics | 2 | 5.0 |
*Immunity, Mucosal | 2 | 11.0 |
Protein p53/genetics | 2 | 1.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Telomerase/metabolism | 2 | 3.0 |
Dendritic Cells/cytology/*immunology | 2 | 3.0 |
*Integrin alpha Chains | 3 | 10.0 |
Lymphocyte Subsets | 3 | 1.0 |
Alternative Splicing/*genetics | 2 | 1.0 |
Colon/metabolism/pathology | 2 | 13.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Thyroid Gland/metabolism | 2 | 3.0 |
Cataract/*metabolism | 2 | 25.0 |
Epithelial Cells/*metabolism | 3 | 2.0 |
Lens, Crystalline/cytology/*metabolism | 2 | 22.0 |
Antigens, CD44/immunology/metabolism | 4 | 100.0 |
Cell Adhesion Molecules/genetics/*physiology | 5 | 33.0 |
*Cytotoxicity, Immunologic/drug effects | 2 | 7.0 |
DNA Fragmentation | 3 | 0.0 |
Leukemia | 3 | 4.0 |
Antibodies | 3 | 0.0 |
Antigens, CD29/biosynthesis | 2 | 25.0 |
Receptors, IgG/biosynthesis | 2 | 7.0 |
Stem Cell Factor | 2 | 2.0 |
Detergents/pharmacology | 3 | 2.0 |
G(M1) Ganglioside/metabolism | 2 | 10.0 |
Glycosylphosphatidylinositols/metabolism | 2 | 3.0 |
*beta-Cyclodextrins | 3 | 7.0 |
Cytokines/*metabolism | 2 | 0.0 |
Colonic Neoplasms/immunology/pathology | 2 | 40.0 |
Antigens, CD44/chemistry/*physiology | 5 | 100.0 |
*Introns | 3 | 1.0 |
Glycoproteins/analysis | 2 | 3.0 |
Antibody Formation | 2 | 0.0 |
Skin Neoplasms/genetics/*immunology/pathology | 2 | 28.0 |
Endothelium, Vascular/immunology | 3 | 7.0 |
Lupus Erythematosus, Systemic/immunology | 2 | 1.0 |
Lymphocyte Subsets/*immunology | 2 | 1.0 |
Autopsy | 2 | 1.0 |
Breast Neoplasms/genetics/*immunology/pathology | 2 | 66.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Bone Marrow Transplantation/*immunology | 3 | 2.0 |
Histocompatibility Testing | 2 | 0.0 |
Integrins/*analysis/genetics | 2 | 66.0 |
Adenocarcinoma/*metabolism/*secondary | 2 | 66.0 |
Colorectal Neoplasms/*metabolism/*pathology | 2 | 50.0 |
Adenocarcinoma/immunology/*pathology | 2 | 13.0 |
Cell Differentiation/*immunology | 2 | 7.0 |
Trabecular Meshwork/cytology/*metabolism | 2 | 50.0 |
Hematopoietic Stem Cells/physiology | 2 | 4.0 |
*Microfilament Proteins | 5 | 10.0 |
Basement Membrane | 2 | 11.0 |
Antigens, CD/analysis/*biosynthesis | 7 | 26.0 |
Plasma Cells/immunology | 2 | 7.0 |
Ankyrins/metabolism | 4 | 40.0 |
Cell Survival | 6 | 0.0 |
Integrins/analysis | 9 | 18.0 |
Proto-Oncogene Proteins c-fos/*genetics | 2 | 8.0 |
Transformation, Genetic | 3 | 1.0 |
Liver Neoplasms/secondary | 5 | 7.0 |
Stimulation, Chemical | 10 | 2.0 |
Lymphatic Metastasis/pathology | 2 | 2.0 |
Antigens, CD44/*blood/genetics | 4 | 100.0 |
Fluorescent Dyes/diagnostic use | 2 | 5.0 |
Genes, Immunoglobulin | 3 | 1.0 |
Immunity, Mucosal | 2 | 2.0 |
Interleukin-1/secretion | 2 | 4.0 |
Intestinal Mucosa/cytology/*immunology | 2 | 13.0 |
Tumor Necrosis Factor-alpha/secretion | 2 | 1.0 |
Antigens, Nuclear | 3 | 2.0 |
Biological Markers/*analysis | 4 | 3.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
Prostatic Neoplasms/chemistry/*pathology | 2 | 16.0 |
Antigens, Differentiation/*genetics | 4 | 2.0 |
Immunization | 2 | 0.0 |
Lymphoid Tissue/immunology | 4 | 11.0 |
Stomach Neoplasms/*metabolism | 3 | 6.0 |
Signal Transduction/drug effects/*immunology | 2 | 5.0 |
Protein Binding/physiology | 2 | 0.0 |
Killer Cells, Natural/*physiology | 2 | 4.0 |
T-Lymphocytes, Cytotoxic/*physiology | 2 | 16.0 |
Hyaluronic Acid/chemistry | 2 | 100.0 |
Protein Interaction Mapping | 3 | 2.0 |
Antigens, CD3/immunology | 4 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 5 | 0.0 |
Antibodies, Monoclonal/*physiology | 2 | 5.0 |
Cell Membrane/*metabolism | 5 | 1.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Lymphocyte Activation/drug effects | 6 | 1.0 |
Laminin/*metabolism | 2 | 5.0 |
Ionophores/pharmacology | 2 | 1.0 |
Antigens, CD44/genetics/immunology/*physiology | 2 | 100.0 |
Precancerous Conditions/*immunology | 2 | 20.0 |
Embryonic and Fetal Development/immunology | 2 | 28.0 |
Skin/metabolism | 3 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 3 | 3.0 |
Mice, Inbred C3H | 3 | 0.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 2 | 4.0 |
Breast Neoplasms/*immunology | 2 | 3.0 |
Gastric Mucosa/metabolism | 3 | 6.0 |
Heparin/metabolism | 3 | 2.0 |
Open Reading Frames | 2 | 0.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
Endometrium/metabolism | 3 | 5.0 |
Dogs/*immunology | 2 | 22.0 |
Epitope Mapping | 3 | 1.0 |
Monocytes/metabolism | 6 | 1.0 |
Neutrophils/metabolism | 4 | 2.0 |
Interferon-alpha/*pharmacology | 4 | 2.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Cell Adhesion/immunology/*physiology | 2 | 100.0 |
L-Selectin/*physiology | 2 | 22.0 |
Adenoma/genetics/metabolism | 2 | 18.0 |
Testicular Neoplasms/*metabolism/pathology | 2 | 11.0 |
Phosphoproteins/biosynthesis | 2 | 5.0 |
Cell Differentiation/*physiology | 5 | 2.0 |
Down-Regulation/physiology | 2 | 2.0 |
Macrophages/metabolism | 3 | 0.0 |
Particle Size | 2 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Lymphoid Tissue/*immunology | 3 | 11.0 |
Adenocarcinoma/*blood | 2 | 14.0 |
CA-15-3 Antigen/genetics | 2 | 14.0 |
Adrenal Gland Neoplasms/*metabolism | 2 | 12.0 |
Actins/physiology | 2 | 5.0 |
Enzyme Induction | 2 | 0.0 |
Protein-Tyrosine Kinase/*biosynthesis | 2 | 8.0 |
Binding, Competitive/immunology | 8 | 8.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 7 | 1.0 |
Interleukin-15/pharmacology | 2 | 8.0 |
Monocytes/immunology/*metabolism | 2 | 4.0 |
Tumor Necrosis Factor-alpha/*physiology | 4 | 1.0 |
Genetic Heterogeneity | 2 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Bone Marrow/metabolism | 5 | 4.0 |
Multigene Family | 5 | 0.0 |
*Hematopoiesis | 7 | 3.0 |
Leukemia, Lymphocytic, Acute/*pathology | 2 | 10.0 |
Carcinoma, Small Cell/immunology/pathology | 2 | 40.0 |
Cytoskeletal Proteins/*analysis | 2 | 12.0 |
Liver/chemistry | 2 | 2.0 |
Intercellular Junctions/chemistry/ultrastructure | 2 | 100.0 |
Keratinocytes/chemistry/ultrastructure | 2 | 50.0 |
Receptors, Cell Surface/*genetics | 8 | 2.0 |
Adenocarcinoma/chemistry/metabolism | 2 | 66.0 |
Genes, myc/*genetics | 4 | 4.0 |
Neuroblastoma/*genetics/*metabolism/pathology | 3 | 60.0 |
Carrier Proteins/*metabolism | 12 | 1.0 |
Genes, myc/genetics | 4 | 5.0 |
Bone Marrow Cells/cytology/*immunology | 2 | 15.0 |
T-Lymphocytes/cytology/immunology | 2 | 2.0 |
*Cell Division | 2 | 1.0 |
DNA, Viral/analysis | 3 | 0.0 |
Herpesvirus 4, Human/genetics | 2 | 2.0 |
Cytoplasm/chemistry/metabolism | 2 | 11.0 |
L Cells (Cell Line) | 3 | 1.0 |
Chimeric Proteins/immunology | 2 | 6.0 |
Extracellular Matrix/immunology | 4 | 44.0 |
Melanoma, Experimental/immunology/*pathology | 2 | 100.0 |
Antigens, CD44/*blood/*genetics | 2 | 100.0 |
Lymph Nodes/metabolism | 2 | 3.0 |
Antigenic Variation | 2 | 6.0 |
Carcinoma, Squamous Cell/immunology | 2 | 7.0 |
Antigens, Neoplasm/*analysis/genetics | 4 | 25.0 |
Polymerase Chain Reaction/methods | 9 | 0.0 |
Receptors, Cytokine/metabolism | 2 | 2.0 |
Synovial Membrane/immunology/*metabolism/pathology | 3 | 75.0 |
*Oncogenes | 3 | 0.0 |
Carcinoma, Renal Cell/*immunology/pathology | 2 | 20.0 |
Histamine Release | 2 | 3.0 |
Kidney Neoplasms/*immunology/pathology | 2 | 16.0 |
Serine Endopeptidases/analysis | 2 | 5.0 |
Glucuronosyltransferase/genetics/metabolism | 2 | 15.0 |
Interleukin-12/pharmacology | 2 | 4.0 |
Thymus Gland/immunology/*pathology | 3 | 37.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
Endothelium/metabolism | 2 | 3.0 |
Hematopoietic Stem Cells/*metabolism | 4 | 3.0 |
Sex Factors | 2 | 0.0 |
Macrophages/*immunology | 3 | 1.0 |
Graves' Disease/*immunology | 2 | 2.0 |
HLA-DR Antigens/*biosynthesis | 2 | 6.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 3 | 3.0 |
Antigens, CD34 | 13 | 2.0 |
*Graft Survival | 2 | 1.0 |
Leukocytes/metabolism/*pathology | 2 | 100.0 |
Transplantation, Autologous | 2 | 0.0 |
Skin/immunology | 4 | 4.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Gene Deletion | 2 | 0.0 |
Antigens, CD18/metabolism | 7 | 15.0 |
Cycloheximide/pharmacology | 6 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 4 | 1.0 |
Embryo Implantation/*physiology | 2 | 5.0 |
Trophoblasts/metabolism | 2 | 5.0 |
Antigens, CD44/genetics/immunology/*metabolism | 2 | 100.0 |
Immunologic Techniques | 7 | 2.0 |
Fibroblasts/cytology/immunology | 2 | 18.0 |
Gingiva/cytology/*immunology | 3 | 21.0 |
Recombinant Proteins | 4 | 0.0 |
Lymphocyte Activation/*physiology | 2 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 2 | 3.0 |
Superantigens/immunology | 2 | 4.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 5 | 11.0 |
Asthma/*immunology | 3 | 3.0 |
RNA/isolation & purification | 2 | 3.0 |
Cytokines/*biosynthesis | 5 | 1.0 |
Interleukin-8/biosynthesis | 2 | 1.0 |
Oligosaccharides/pharmacology | 2 | 22.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 4 | 0.0 |
Antigens, CD14/analysis | 5 | 4.0 |
Colitis, Ulcerative/*immunology | 2 | 5.0 |
Crohn Disease/*immunology | 2 | 5.0 |
Macrophage-1 Antigen/analysis | 3 | 6.0 |
Receptors, IgG/analysis | 4 | 6.0 |
Glioblastoma/*metabolism | 2 | 6.0 |
Schwann Cells/*metabolism | 2 | 12.0 |
Hematopoietic Stem Cells/immunology | 4 | 5.0 |
Cytochalasin B/pharmacology | 6 | 6.0 |
Glioma | 2 | 2.0 |
Antigens, CD2/metabolism | 2 | 7.0 |
Immunoglobulin M/genetics | 2 | 13.0 |
Antibodies, Anti-Idiotypic/pharmacology | 2 | 6.0 |
Antigens, Differentiation/analysis | 13 | 4.0 |
Interleukin-4/*physiology | 2 | 4.0 |
Interleukin-6/physiology | 2 | 3.0 |
Signal Transduction/genetics | 3 | 1.0 |
Antigens, CD/*biosynthesis/genetics | 4 | 6.0 |
Oncogenes | 2 | 0.0 |
Administration, Topical | 2 | 1.0 |
Cell Membrane/*chemistry | 2 | 6.0 |
Membrane Proteins/*analysis | 3 | 4.0 |
Antigens, Surface/biosynthesis | 6 | 10.0 |
Cytotoxicity, Immunologic/drug effects | 2 | 1.0 |
Histocompatibility Antigens Class I/*metabolism | 2 | 2.0 |
Receptors, Immunologic/*physiology | 4 | 2.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 2 | 4.0 |
Colony-Forming Units Assay | 5 | 0.0 |
Erythropoietin/pharmacology | 2 | 1.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 3 | 1.0 |
Leukocytes/*chemistry | 2 | 7.0 |
Mouth Mucosa/*metabolism | 2 | 22.0 |
Antigens, CD18/biosynthesis | 2 | 22.0 |
Escherichia coli/metabolism | 3 | 1.0 |
Cell Separation/methods | 5 | 3.0 |
Gene Transfer Techniques | 3 | 0.0 |
Zinc Fingers | 2 | 0.0 |
Blood Proteins/analysis | 2 | 1.0 |
Membrane Proteins/analysis | 2 | 1.0 |
Chromosome Disorders | 2 | 0.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Brain Neoplasms/*pathology | 2 | 2.0 |
Melanoma/*immunology/pathology | 2 | 8.0 |
Skin Neoplasms/*immunology/pathology | 2 | 10.0 |
Epithelium/chemistry/metabolism | 4 | 25.0 |
*Bone Marrow Cells | 21 | 8.0 |
Histocompatibility Antigens Class II/analysis | 3 | 1.0 |
Cell Membrane/ultrastructure | 3 | 6.0 |
Fibroblasts/pathology | 3 | 4.0 |
Fibroblast Growth Factor 2/*pharmacology | 2 | 1.0 |
Neovascularization, Pathologic/*physiopathology | 2 | 2.0 |
Umbilical Veins/cytology | 3 | 1.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
*Glycoside Hydrolases | 2 | 40.0 |
Heparitin Sulfate/chemistry | 2 | 33.0 |
Skin/*chemistry | 3 | 9.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
*Signal Transduction/drug effects | 3 | 3.0 |
Phagocytosis/*immunology | 2 | 3.0 |
Exons/*immunology | 3 | 60.0 |
Neoplasm Metastasis/immunology | 3 | 75.0 |
Neural Cell Adhesion Molecules/*metabolism | 2 | 10.0 |
Skin Neoplasms/genetics/*metabolism | 2 | 18.0 |
*HIV-1 | 2 | 0.0 |
Heparan Sulfate Proteoglycan | 6 | 18.0 |
Cadherins/*physiology | 3 | 14.0 |
Calcium/pharmacology | 2 | 0.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Indoles/pharmacology | 2 | 0.0 |
Neuroblastoma/*metabolism | 2 | 3.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Antigen Presentation/physiology | 2 | 16.0 |
Rats, Inbred Strains | 4 | 0.0 |
Skin/cytology | 2 | 1.0 |
Up-Regulation/immunology | 5 | 3.0 |
Genes, p53/genetics | 2 | 0.0 |
Bone Morphogenetic Proteins/metabolism | 2 | 3.0 |
Cartilage, Articular/*metabolism | 3 | 18.0 |
Osteoarthritis/*metabolism | 2 | 10.0 |
Proteoglycans/biosynthesis/metabolism | 2 | 66.0 |
RNA/metabolism | 3 | 0.0 |
Rheology | 2 | 2.0 |
Histocompatibility Antigens Class II/biosynthesis | 2 | 4.0 |
Monocytes/drug effects/*immunology/metabolism | 2 | 15.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Leukapheresis | 4 | 3.0 |
Receptors, Lymphocyte Homing/metabolism | 16 | 43.0 |
Fibroblasts/metabolism/pathology | 4 | 9.0 |
Microscopy, Electron, Scanning | 4 | 1.0 |
Heparitin Sulfate/metabolism | 2 | 5.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism | 2 | 3.0 |
Melanoma/*pathology | 3 | 5.0 |
Antigens, CD/analysis/biosynthesis | 3 | 18.0 |
Receptors, Estrogen/*analysis | 2 | 0.0 |
Epithelial Cells | 14 | 2.0 |
Lung/cytology | 2 | 3.0 |
Membrane Glycoproteins/genetics | 4 | 2.0 |
Proto-Oncogene Protein c-kit | 4 | 5.0 |
Carcinoma in Situ/metabolism | 2 | 16.0 |
Cell Adhesion Molecules/*analysis/physiology | 3 | 33.0 |
Cell Communication/immunology | 5 | 6.0 |
T-Lymphocytes/*cytology/immunology | 2 | 4.0 |
Neoplasms/*pathology/physiopathology | 2 | 66.0 |
Mammals | 3 | 0.0 |
Antibodies, Monoclonal/*immunology | 19 | 2.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 2 | 4.0 |
Hematopoietic Stem Cells/*cytology/drug effects/immunology | 3 | 17.0 |
Burkitt Lymphoma/*immunology/pathology | 2 | 50.0 |
Lymph Nodes/immunology/pathology | 3 | 7.0 |
Lymphoma, B-Cell/*immunology/pathology | 2 | 14.0 |
Membrane Proteins/physiology | 2 | 2.0 |
Receptors, Transforming Growth Factor beta/*metabolism | 2 | 7.0 |
Cell Adhesion/drug effects/immunology | 6 | 30.0 |
RNA Splice Sites | 2 | 6.0 |
Antigens, Differentiation/biosynthesis | 3 | 5.0 |
N-Glycosyl Hydrolases/biosynthesis | 2 | 28.0 |
Antigens, CD56/analysis | 2 | 3.0 |
L-Selectin/analysis | 2 | 10.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Integrins/analysis/physiology | 2 | 100.0 |
Fibronectins/physiology | 5 | 14.0 |
Autoradiography | 2 | 0.0 |
Colorectal Neoplasms/diagnosis/*genetics | 2 | 22.0 |
Bronchoalveolar Lavage Fluid | 2 | 4.0 |
HLA Antigens/*analysis | 2 | 0.0 |
Macrophages, Alveolar/*immunology | 2 | 4.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
Thrombospondins | 2 | 1.0 |
Antigens, CD/*immunology/metabolism | 2 | 6.0 |
Cell Aggregation/immunology | 4 | 20.0 |
Hybridomas | 2 | 1.0 |
Interleukin-1/immunology | 2 | 4.0 |
Macrophages/cytology/immunology | 2 | 10.0 |
B-Lymphocytes/*ultrastructure | 2 | 33.0 |
Lymphoma, B-Cell/*pathology | 2 | 8.0 |
B-Lymphocytes/*cytology | 2 | 3.0 |
Endothelium, Vascular/*cytology | 7 | 4.0 |
Cricetulus | 4 | 0.0 |
Receptors, Interleukin-2/biosynthesis | 3 | 2.0 |
Mucous Membrane/metabolism | 2 | 6.0 |
Receptors, Lymphocyte Homing/biosynthesis/*physiology | 3 | 75.0 |
*Embryonic and Fetal Development | 4 | 3.0 |
Antigens, CD45/*analysis | 3 | 6.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Synovial Membrane/cytology/*immunology | 2 | 33.0 |
Antigens, CD95/*physiology | 2 | 2.0 |
Fibroblasts | 2 | 0.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Endothelium, Vascular/cytology | 4 | 1.0 |
Asthma/*immunology/pathology | 2 | 15.0 |
Cell Adhesion Molecules/analysis/*physiology | 4 | 57.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 7 | 17.0 |
Lymphocytes/*physiology | 7 | 8.0 |
Herpesvirus 4, Human/*isolation & purification | 2 | 5.0 |
Endothelium/cytology | 4 | 10.0 |
Genes, Structural | 8 | 0.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Receptors, Cell Surface/biosynthesis | 8 | 22.0 |
Transcription Factors/*biosynthesis | 2 | 1.0 |
Neuroblastoma/genetics/*metabolism/pathology | 2 | 25.0 |
Carrier Proteins/immunology | 4 | 10.0 |
Cell Adhesion/*immunology | 4 | 20.0 |
Intercellular Adhesion Molecule-1/physiology | 4 | 16.0 |
Receptors, Very Late Antigen/physiology | 5 | 41.0 |
Tumor Necrosis Factor-alpha/*analysis | 2 | 0.0 |
Kidney Neoplasms/*metabolism/pathology | 2 | 6.0 |
Leukemia, B-Cell, Chronic/*metabolism | 2 | 16.0 |
Tissue Fixation | 4 | 4.0 |
Antigens, Viral, Tumor/biosynthesis | 2 | 100.0 |
Bone Marrow/physiology | 2 | 6.0 |
Culture Techniques/methods | 2 | 3.0 |
Gene Expression Regulation, Leukemic/drug effects | 2 | 8.0 |
Receptors, Lymphocyte Homing/biosynthesis/genetics/*physiology | 2 | 100.0 |
Asthma/*metabolism/pathology | 2 | 40.0 |
Cell Membrane/chemistry/ultrastructure | 2 | 25.0 |
Multiple Myeloma/metabolism/*pathology | 3 | 15.0 |
Neoplasm Circulating Cells | 2 | 7.0 |
Neoplasm Proteins/*physiology | 6 | 6.0 |
Proteoglycans/physiology | 2 | 28.0 |
Endothelium, Vascular/*metabolism/pathology | 2 | 5.0 |
Receptors, Laminin/physiology | 2 | 50.0 |
Macrophages/cytology | 2 | 2.0 |
Antigens, CD44/*chemistry/*metabolism | 2 | 100.0 |
Chondroitin Lyases | 2 | 100.0 |
Immunotherapy | 3 | 0.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Radioimmunodetection | 2 | 11.0 |
Skin Neoplasms/*immunology | 3 | 8.0 |
Cyclin D1/metabolism | 2 | 1.0 |
Cyclins/metabolism | 3 | 0.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Prostaglandin-Endoperoxide Synthase/*metabolism | 2 | 3.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Tumor Suppressor Proteins/metabolism | 2 | 1.0 |
Colchicine/pharmacology | 2 | 3.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Antigens, CD44/*genetics/immunology | 2 | 100.0 |
HIV-1/*physiology | 5 | 1.0 |
Sulfates | 2 | 25.0 |
RNA, Messenger/analysis/biosynthesis | 3 | 1.0 |
Cytotoxicity Tests, Immunologic | 4 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 3 | 1.0 |
Growth Substances/genetics | 2 | 3.0 |
Hematopoietic Stem Cells/chemistry | 2 | 13.0 |
Interleukin-6/blood | 2 | 0.0 |
Interleukin-8/blood | 2 | 2.0 |
Integrin alpha1beta1 | 2 | 14.0 |
Genetic Vectors | 2 | 0.0 |
*Transfection | 2 | 0.0 |
Capillaries/metabolism | 2 | 8.0 |
Fibroblasts/*immunology | 2 | 11.0 |
RNA-Directed DNA Polymerase | 3 | 2.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Epitopes/*immunology | 2 | 0.0 |
Antigen Presentation | 2 | 0.0 |
Receptors, Antigen, T-Cell/*immunology | 3 | 1.0 |
Spleen/immunology/pathology | 2 | 11.0 |
Antigens, CD44/analysis/genetics/*physiology | 3 | 100.0 |
RNA, Neoplasm/*genetics | 2 | 11.0 |
Lymphocyte Subsets/immunology | 2 | 1.0 |
Leukemia/*metabolism/pathology | 2 | 11.0 |
Lymphocytes/*metabolism | 3 | 1.0 |
Neoplasms/*metabolism/*pathology | 2 | 15.0 |
Lymphoma, B-Cell/*metabolism/pathology | 2 | 13.0 |
RNA, Neoplasm/analysis | 6 | 2.0 |
Membrane Glycoproteins/*physiology | 6 | 2.0 |
Protein Folding | 2 | 0.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Antigens, CD44 | 175 | 94.0 |
Neoplasm Metastasis/genetics/*immunology | 2 | 100.0 |
Epidermis/cytology/*immunology | 2 | 28.0 |
Lymphocyte Function-Associated Antigen-1/*immunology | 5 | 25.0 |
Antigens, CD/biosynthesis/immunology | 2 | 7.0 |
*Cell Adhesion/drug effects | 3 | 13.0 |
Intercellular Adhesion Molecule-1/biosynthesis/immunology | 2 | 40.0 |
Monocytes/*virology | 3 | 13.0 |
Ovarian Neoplasms/drug therapy/*metabolism/pathology | 2 | 33.0 |
Peritoneal Neoplasms/*secondary | 2 | 25.0 |
Antigens, CD45/physiology | 2 | 13.0 |
*Phagocytosis | 2 | 1.0 |
Cell Division/immunology | 5 | 1.0 |
Dendritic Cells/*cytology/*immunology | 2 | 13.0 |
Antigens, CD5/analysis | 2 | 4.0 |
Epithelium/immunology/pathology | 2 | 7.0 |
Cell Adhesion/drug effects/*immunology | 2 | 50.0 |
Tetradecanoylphorbol Acetate | 3 | 4.0 |
Lymphoma/*immunology | 2 | 6.0 |
Receptors, Tumor Necrosis Factor, Type II | 2 | 0.0 |
Aneuploidy | 2 | 1.0 |
Antigens, CD3/*metabolism | 3 | 6.0 |
Multiple Myeloma/*metabolism | 4 | 14.0 |
Lymphocyte Activation/physiology | 2 | 2.0 |
Transcription Factors/genetics/*physiology | 2 | 1.0 |
Colonic Neoplasms | 4 | 2.0 |
Antigens, CD44/*immunology/metabolism | 3 | 100.0 |
Hyaluronoglucosaminidase | 2 | 33.0 |
Dendritic Cells/immunology | 3 | 2.0 |
*Carotid Artery Injuries | 2 | 33.0 |
Hyaluronic Acid/*biosynthesis/metabolism | 3 | 75.0 |
Interleukin-2/biosynthesis | 4 | 0.0 |
Antigens, CD44/classification/*genetics | 2 | 100.0 |
Sequence Analysis | 2 | 0.0 |
Melanoma/chemistry/genetics/secondary | 2 | 100.0 |
B-Lymphocytes | 2 | 1.0 |
Growth Substances/physiology | 2 | 1.0 |
Helicobacter pylori | 2 | 5.0 |
Microsatellite Repeats | 2 | 0.0 |
Cell Movement/immunology/*physiology | 2 | 50.0 |
Inflammation/*immunology/metabolism | 2 | 40.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Gene Targeting | 2 | 0.0 |
HIV-1/*genetics | 2 | 0.0 |
Oligodeoxyribonucleotides/chemistry | 4 | 1.0 |
Virus Replication | 2 | 0.0 |
Bone Marrow/immunology/pathology | 2 | 5.0 |
Integrins/analysis/*biosynthesis | 3 | 100.0 |
Receptors, Lymphocyte Homing/analysis/*biosynthesis | 6 | 100.0 |
Interleukin-1/physiology | 2 | 2.0 |
Down-Regulation/*physiology | 2 | 6.0 |
Skin/chemistry | 3 | 8.0 |
Antigens, CD44/*chemistry | 3 | 100.0 |
Conserved Sequence | 3 | 0.0 |
Lectins | 2 | 2.0 |
Proteoglycans/*chemistry | 2 | 40.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Cyclic AMP/*physiology | 2 | 2.0 |
Glioma/*metabolism | 2 | 4.0 |
Proto-Oncogene Proteins c-jun/biosynthesis | 2 | 10.0 |
Epitopes/analysis | 9 | 3.0 |
Molecular Probes/genetics | 2 | 2.0 |
Skin Neoplasms/*chemistry | 2 | 20.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Macrophage Colony-Stimulating Factor/pharmacology | 2 | 2.0 |
Receptors, IgG/metabolism | 4 | 5.0 |
Neovascularization, Physiologic/*physiology | 2 | 1.0 |
Brain Neoplasms/*chemistry/secondary | 2 | 100.0 |
Glioma/chemistry | 2 | 50.0 |
Endocytosis | 2 | 0.0 |
Carcinoma, Squamous Cell/*immunology | 2 | 7.0 |
Hematopoiesis/physiology | 2 | 4.0 |
Hematopoietic Cell Growth Factors/physiology | 2 | 13.0 |
Receptors, Lymphocyte Homing/physiology | 11 | 50.0 |
Lung Neoplasms/*chemistry/immunology | 2 | 100.0 |
Antigens, CD8/genetics | 2 | 13.0 |
*Homeodomain Proteins | 3 | 1.0 |
Antigens, Surface/analysis/genetics | 2 | 33.0 |
Cell Adhesion Molecules/analysis/genetics | 2 | 66.0 |
Interferon-alpha/therapeutic use | 2 | 5.0 |
*Cysteine | 2 | 5.0 |
Receptors, Very Late Antigen/metabolism | 2 | 18.0 |
Brazil | 2 | 0.0 |
Necrosis | 2 | 0.0 |
B-Lymphocytes/immunology/*metabolism | 3 | 5.0 |
Oligonucleotide Probes | 7 | 1.0 |
Restriction Mapping | 10 | 0.0 |
Carcinoma/*genetics | 4 | 3.0 |
Leukemia/*pathology | 2 | 4.0 |
Cell Adhesion/drug effects/*physiology | 2 | 6.0 |
Dexamethasone/pharmacology | 4 | 0.0 |
Neutrophils/drug effects/*metabolism | 2 | 3.0 |
Lymphocytes/*immunology/metabolism | 3 | 13.0 |
Lymphocyte Function-Associated Antigen-1/*analysis | 3 | 37.0 |
Fibronectins/pharmacology | 4 | 8.0 |
Interleukin-1/*biosynthesis | 3 | 2.0 |
Consensus Sequence | 2 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Epithelium/chemistry/immunology | 2 | 25.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Rats, Inbred F344 | 3 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Chemokines, CXC/*metabolism | 2 | 3.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Proteoglycans/biosynthesis/*metabolism | 2 | 50.0 |
Melanoma/genetics/*metabolism | 2 | 12.0 |
Cell Adhesion Molecules/*biosynthesis/genetics | 3 | 18.0 |
Intestinal Mucosa/immunology | 2 | 3.0 |
Extracellular Matrix/*immunology | 2 | 100.0 |
Bromelains/*pharmacology | 4 | 80.0 |
Binding Sites, Antibody | 3 | 0.0 |
Fibronectins/*metabolism | 2 | 2.0 |
Integrins/*immunology | 2 | 12.0 |
Receptors, Lymphocyte Homing/*immunology | 13 | 68.0 |
T-Lymphocytes/immunology/*metabolism | 3 | 3.0 |
Blood Group Antigens/*genetics | 2 | 1.0 |
Proteoglycans/*analysis | 2 | 20.0 |
Basal Ganglia Diseases/*pathology | 2 | 100.0 |
Cytoskeleton/*pathology | 2 | 22.0 |
HTLV-I Infections/*immunology | 2 | 12.0 |
Microscopy, Phase-Contrast | 4 | 4.0 |
Serine Endopeptidases/metabolism | 2 | 1.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
RNA/genetics/metabolism | 2 | 1.0 |
Stromal Cells/*physiology | 2 | 8.0 |
Trypsin/metabolism | 2 | 1.0 |
Bone Neoplasms/*secondary | 2 | 20.0 |
Colonic Neoplasms/metabolism/*pathology | 2 | 8.0 |
Vinculin/analysis | 2 | 28.0 |
Neoplasms/immunology/*pathology | 3 | 75.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
T-Lymphocytes | 2 | 0.0 |
Cytoskeleton/*physiology | 2 | 5.0 |
Prostatic Neoplasms | 2 | 3.0 |
Epitopes/*analysis | 5 | 3.0 |
Adjuvants, Immunologic/*administration & dosage | 2 | 6.0 |
Lung Neoplasms/*chemistry | 4 | 22.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Antigens, CD44/*analysis/chemistry | 2 | 100.0 |
Carcinoma/chemistry | 2 | 20.0 |
Pancreatic Neoplasms/*chemistry | 2 | 20.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Proteoglycans/biosynthesis | 2 | 18.0 |
Antigens, CD44/biosynthesis/genetics/*physiology | 2 | 100.0 |
Antigens, Neoplasm/*analysis/immunology | 2 | 11.0 |
Antigens, CD29/*biosynthesis | 2 | 50.0 |
Genes, Immunoglobulin/immunology | 2 | 50.0 |
Antigens, Differentiation/*metabolism | 5 | 4.0 |
Alkaloids/pharmacology | 6 | 5.0 |
Lymphocyte Function-Associated Antigen-1/*physiology | 6 | 14.0 |
Protein Kinase C/antagonists & inhibitors/physiology | 2 | 9.0 |
Staurosporine | 6 | 6.0 |
T-Lymphocytes/*cytology | 4 | 4.0 |
Tumor Cells, Cultured/immunology | 2 | 2.0 |
Papio | 2 | 1.0 |
Antigens, Differentiation/*immunology | 4 | 2.0 |
HLA-DR Antigens/biosynthesis | 2 | 2.0 |
Lymphocyte Function-Associated Antigen-1/biosynthesis | 4 | 19.0 |
Neoplasm Invasiveness/genetics | 2 | 4.0 |
Receptors, Lymphocyte Homing/genetics | 3 | 60.0 |
Epithelium/metabolism/microbiology | 2 | 50.0 |
Endothelium, Vascular/*physiology | 5 | 3.0 |
Cytoskeleton/drug effects/physiology | 2 | 40.0 |
Antigens, CD44/analysis/*physiology | 3 | 100.0 |
Cell Adhesion Molecules/analysis/biosynthesis | 2 | 40.0 |
Tumor Cells, Cultured/immunology/metabolism | 2 | 12.0 |
Receptors, Lymphocyte Homing/genetics/*metabolism | 8 | 100.0 |
Cyclodextrins/pharmacology | 2 | 7.0 |
Fluorescein-5-isothiocyanate/pharmacology | 2 | 25.0 |
Carboplatin/administration & dosage | 2 | 4.0 |
Neoplasm Recurrence, Local/drug therapy/metabolism/pathology | 2 | 100.0 |
Multiple Myeloma/*metabolism/pathology | 2 | 10.0 |
Gels | 2 | 2.0 |
Radioimmunoassay | 2 | 0.0 |
Antigens, CD11/*immunology | 2 | 66.0 |
Carrier Proteins/biosynthesis | 6 | 10.0 |
L-Selectin | 29 | 46.0 |
Receptors, Very Late Antigen/biosynthesis | 2 | 66.0 |
Carrier Proteins/*immunology | 5 | 11.0 |
*Immunity, Cellular | 2 | 1.0 |
Receptors, Cell Surface/*immunology | 5 | 6.0 |
Vascular Cell Adhesion Molecule-1 | 15 | 18.0 |
Carrier Proteins/*analysis | 23 | 27.0 |
Receptors, Cell Surface/*analysis | 24 | 20.0 |
Receptors, Lymphocyte Homing/*analysis | 34 | 89.0 |
Polysaccharides/*metabolism | 2 | 8.0 |
Antigens, CD56 | 3 | 4.0 |
Phorbol 12,13-Dibutyrate/*pharmacology | 2 | 11.0 |
Antigens, Differentiation/immunology | 3 | 2.0 |
Receptors, Cell Surface/immunology | 3 | 8.0 |
Receptors, Lymphocyte Homing/immunology | 5 | 35.0 |
Carrier Proteins/*genetics | 6 | 0.0 |
Receptors, Lymphocyte Homing/*genetics | 21 | 100.0 |
Cytokines/genetics | 2 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics | 2 | 1.0 |
Receptors, Lymphocyte Homing/*analysis/*genetics | 3 | 100.0 |
Synovial Fluid/*immunology | 2 | 3.0 |
Gastric Mucosa/*chemistry | 2 | 15.0 |
Carrier Proteins/*analysis/genetics/immunology | 2 | 66.0 |
Receptors, Cell Surface/*analysis/genetics/immunology | 2 | 66.0 |
Receptors, Lymphocyte Homing/*analysis/genetics/immunology | 2 | 66.0 |
Exons/immunology | 2 | 15.0 |
Antigens, CD4/physiology | 2 | 2.0 |
Carrier Proteins/*physiology | 11 | 5.0 |
Carrier Proteins/*analysis/genetics | 8 | 33.0 |
Receptors, Cell Surface/*analysis/genetics | 8 | 57.0 |
Receptors, Lymphocyte Homing/*analysis/genetics | 9 | 100.0 |
Interleukin-2/physiology | 3 | 3.0 |
Melanoma/immunology | 2 | 5.0 |
Carrier Proteins/*analysis/*genetics | 2 | 40.0 |
Receptors, Cell Surface/*analysis/*genetics | 2 | 100.0 |
Bone Marrow/drug effects | 2 | 2.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Carrier Proteins/*biosynthesis/genetics | 3 | 5.0 |
Receptors, Cell Surface/*biosynthesis/genetics | 3 | 13.0 |
Receptors, Lymphocyte Homing/*biosynthesis/genetics | 4 | 80.0 |
Antigens, CD40 | 4 | 7.0 |
Apoptosis/immunology | 2 | 2.0 |
Proto-Oncogene Proteins/biosynthesis | 2 | 1.0 |
Carrier Proteins/*analysis/chemistry/genetics | 2 | 100.0 |
Receptors, Cell Surface/*analysis/chemistry/genetics | 2 | 100.0 |
Receptors, Lymphocyte Homing/*analysis/chemistry/genetics | 3 | 100.0 |
Carrier Proteins/analysis/*biosynthesis | 3 | 33.0 |
Receptors, Cell Surface/analysis/*biosynthesis | 3 | 60.0 |
Antigens, CD/immunology/metabolism | 2 | 3.0 |
Integrins/immunology | 2 | 9.0 |
Keratinocytes/*metabolism | 3 | 3.0 |
Lectins/*metabolism | 5 | 8.0 |
Peanut Agglutinin | 2 | 6.0 |
Cell Adhesion Molecules/*analysis/blood | 2 | 50.0 |
Antigens, CD/immunology/*metabolism | 2 | 4.0 |
Antigens, CD59 | 3 | 1.0 |
Carrier Proteins/analysis | 12 | 13.0 |
E-Selectin | 7 | 8.0 |
P-Selectin | 3 | 5.0 |
Receptors, Cell Surface/analysis | 12 | 15.0 |
Receptors, Cell Surface/*biosynthesis | 4 | 7.0 |
Receptors, Lymphocyte Homing/*biosynthesis | 6 | 60.0 |
HLA-DR Antigens/metabolism | 2 | 1.0 |
Macrophages/physiology | 2 | 2.0 |
Superoxides/metabolism | 2 | 0.0 |
Receptors, Immunologic/*metabolism | 3 | 1.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 2 | 3.0 |
Liver Neoplasms/*metabolism/pathology | 2 | 2.0 |
Pancreas/chemistry | 2 | 8.0 |
Horses | 3 | 2.0 |
Thymus Gland/immunology | 2 | 3.0 |
Carrier Proteins/biosynthesis/*physiology | 2 | 25.0 |
Receptors, Cell Surface/biosynthesis/*physiology | 2 | 40.0 |
Burkitt Lymphoma/immunology/*pathology | 2 | 28.0 |
Tonsil/*immunology | 3 | 17.0 |
Immunophenotyping/methods | 2 | 4.0 |
Macrophage Inflammatory Protein-1 | 2 | 10.0 |
Keratinocytes/*immunology | 2 | 11.0 |
Cell Adhesion Molecules/genetics/*metabolism | 2 | 4.0 |
Receptors, Cell Surface/chemistry/*genetics | 2 | 9.0 |
Receptors, Lymphocyte Homing/chemistry/*genetics | 2 | 100.0 |
Antigens/immunology | 3 | 2.0 |
Hematopoietic Stem Cells/cytology/*immunology | 2 | 4.0 |
Diclofenac/*administration & dosage/therapeutic use | 2 | 100.0 |
Drug Delivery Systems | 2 | 2.0 |
*Hyaluronic Acid | 3 | 100.0 |
Palliative Care | 2 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 2 | 3.0 |
Carbohydrates/*metabolism | 2 | 5.0 |
Receptors, Immunologic/metabolism | 3 | 1.0 |
Neoplasm Metastasis/*immunology | 3 | 23.0 |
*Genes, myc | 3 | 1.0 |
Antigens, CD18/*blood | 2 | 40.0 |
Breast Neoplasms/chemistry | 2 | 11.0 |
Antigens, CD29 | 3 | 4.0 |
Antigens/analysis | 2 | 1.0 |
*Adenosinetriphosphatase | 2 | 2.0 |
DNA, Neoplasm/analysis/genetics | 2 | 2.0 |
Chromium Radioisotopes | 2 | 16.0 |
Antibodies, Bispecific/immunology | 2 | 33.0 |
Cytotoxicity, Immunologic/*immunology | 3 | 6.0 |
Interleukin-6/*physiology | 2 | 2.0 |
Histocompatibility Antigens Class I/biosynthesis | 2 | 4.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Receptors, Lymphocyte Homing/*analysis/physiology | 3 | 100.0 |
Synovial Membrane/*immunology/pathology | 2 | 16.0 |
Glioma/*immunology | 2 | 13.0 |
Receptors, Lymphocyte Homing/*analysis/immunology | 2 | 100.0 |
T-Lymphocyte Subsets/*physiology | 2 | 6.0 |
Longitudinal Studies | 2 | 0.0 |
Extracellular Matrix | 2 | 8.0 |
Lymph Nodes/*immunology | 2 | 5.0 |
Immunosorbent Techniques | 2 | 0.0 |
Carrier Proteins/analysis/*physiology | 3 | 25.0 |
Receptors, Cell Surface/analysis/*physiology | 3 | 27.0 |
Receptors, Lymphocyte Homing/analysis/*physiology | 4 | 100.0 |
Adenosine Diphosphate Ribose/metabolism | 2 | 3.0 |
Carrier Proteins/immunology/*metabolism | 2 | 10.0 |
Fibronectins/chemistry/*metabolism | 2 | 33.0 |
Heparin/*metabolism | 2 | 2.0 |
Receptors, Cell Surface/immunology/*metabolism | 2 | 6.0 |
Receptors, Lymphocyte Homing/immunology/*metabolism | 4 | 100.0 |
Receptors, Cell Surface/immunology/*physiology | 2 | 13.0 |
Membrane Glycoproteins/*analysis | 5 | 3.0 |
Receptors, Fibronectin | 2 | 16.0 |
Intercellular Adhesion Molecule-1 | 29 | 12.0 |
Antigens, CD2 | 22 | 4.0 |
Antigens, CD3/*immunology | 3 | 2.0 |
Antigens, CD58 | 15 | 10.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Glioma/immunology | 2 | 28.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Receptors, Cell Surface/antagonists & inhibitors/*physiology | 2 | 50.0 |
Receptors, Lymphocyte Homing/antagonists & inhibitors/*physiology | 2 | 100.0 |
Skin Neoplasms/immunology/*pathology | 2 | 7.0 |
B-Lymphocyte Subsets/*immunology | 4 | 5.0 |
Interleukin-4/immunology | 2 | 3.0 |
Receptors, Very Late Antigen/analysis | 2 | 25.0 |
T-Lymphocyte Subsets/cytology/*immunology | 2 | 8.0 |
Chromosome Aberrations | 2 | 0.0 |
Gene Rearrangement | 3 | 0.0 |
Antigens, CD | 6 | 4.0 |
Cell Membrane/immunology/metabolism | 3 | 2.0 |
Antigens, CD5 | 2 | 0.0 |
Lymphadenitis/pathology | 2 | 40.0 |
Tonsillitis/pathology | 2 | 100.0 |
Rosette Formation | 3 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Proto-Oncogene Proteins/analysis | 2 | 1.0 |
Receptor Protein-Tyrosine Kinases/analysis | 2 | 4.0 |
Receptors, Colony-Stimulating Factor/analysis | 2 | 25.0 |
Carrier Proteins/genetics/*physiology | 2 | 2.0 |
Receptors, Cell Surface/genetics/*physiology | 2 | 3.0 |
Receptors, Lymphocyte Homing/genetics/*physiology | 3 | 100.0 |
Transcription Factors/analysis | 2 | 2.0 |
Cell Adhesion Molecules, Neuronal/physiology | 2 | 40.0 |
Receptors, Lymphocyte Homing/biosynthesis/*genetics | 4 | 80.0 |
Antigens, Neoplasm/biosynthesis | 3 | 18.0 |
Antigen-Presenting Cells/immunology | 3 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 2 | 0.0 |
Receptors, Immunologic/*immunology | 3 | 2.0 |
Neoplasms/*immunology | 2 | 1.0 |
Mice, Inbred Strains | 2 | 0.0 |
T-Lymphocyte Subsets/*cytology | 2 | 7.0 |
Protein Subunits/metabolism | 2 | 4.0 |
Receptors, Antigen, T-Cell, gamma-delta/metabolism | 2 | 15.0 |
Immunotherapy, Adoptive | 2 | 2.0 |
*Proto-Oncogenes | 2 | 0.0 |
Antigens, CD4/*analysis | 2 | 1.0 |
Biological Transport | 2 | 0.0 |
Cytoplasm/pathology | 2 | 7.0 |
DNA | 2 | 0.0 |
Cathepsins/genetics | 2 | 25.0 |
Cell Adhesion Molecules/analysis/physiology | 2 | 40.0 |
Magnesium/pharmacology | 3 | 2.0 |
Antigens, CD3 | 10 | 2.0 |
Antigens, CD4 | 2 | 2.0 |
Antigens, CD8 | 2 | 0.0 |
Antigens, CD4/biosynthesis | 2 | 2.0 |
Thymus Gland/*immunology | 2 | 3.0 |
Carcinoma/metabolism | 2 | 3.0 |
Lung Neoplasms/metabolism | 2 | 5.0 |
Antibody-Dependent Cell Cytotoxicity | 2 | 2.0 |
Monocytes/physiology | 2 | 1.0 |
Skin Neoplasms/*metabolism | 2 | 5.0 |
Antigens, CD45 | 13 | 5.0 |
Membrane Glycoproteins | 3 | 6.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
Basement Membrane/immunology | 2 | 3.0 |
Antigens, CD31 | 3 | 8.0 |
Receptors, Lymphocyte Homing/*chemistry | 3 | 100.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
Kidney Neoplasms/mortality/*pathology | 2 | 50.0 |
Neuroglia/*metabolism | 3 | 6.0 |
Antigens, CD11 | 3 | 3.0 |
Antigens, CD18 | 5 | 5.0 |
T-Lymphocytes/immunology/*physiology | 4 | 7.0 |
Antigens, CD19 | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 3 | 2.0 |
Proto-Oncogene Proteins/*biosynthesis/genetics | 2 | 2.0 |
Antigens, Differentiation/*physiology | 4 | 4.0 |
Multiple Myeloma/*immunology | 2 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 6 | 3.0 |
Cell Adhesion Molecules/*immunology/metabolism | 2 | 50.0 |
Receptors, Immunologic/immunology | 5 | 4.0 |
Receptors, Lymphocyte Homing/*genetics/metabolism | 2 | 100.0 |
DNA, Single-Stranded | 2 | 2.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
Drug Resistance/*genetics | 2 | 4.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*physiology | 2 | 2.0 |
Cartilage, Articular/metabolism | 3 | 23.0 |
Receptors, Lymphocyte Homing/chemistry/*metabolism | 4 | 100.0 |
Drug Therapy | 2 | 14.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
Antigens, Surface/*physiology | 3 | 4.0 |
T-Lymphocytes/*immunology/physiology | 2 | 5.0 |
Azepines/pharmacology | 2 | 9.0 |
Brain Neoplasms/*immunology | 2 | 15.0 |
Histocompatibility Antigens/*physiology | 2 | 16.0 |
Receptors, Very Late Antigen/*physiology | 2 | 16.0 |
*Gene Rearrangement | 2 | 0.0 |
Brain/cytology | 2 | 7.0 |
Histocompatibility Antigens/analysis | 4 | 6.0 |
Antigens, CD28 | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/physiology | 6 | 7.0 |
Receptors, Antigen, T-Cell/physiology | 4 | 2.0 |
Interleukin-6/*metabolism | 2 | 1.0 |
Up-Regulation/genetics | 3 | 3.0 |
Antigens, Neoplasm/immunology | 2 | 1.0 |
RNA/biosynthesis | 2 | 2.0 |
Cyclosporins/pharmacology | 3 | 7.0 |
Antigens, CD55 | 2 | 1.0 |
Glycolipids/analysis | 2 | 16.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 3 | 1.0 |
Receptors, Antigen, T-Cell/analysis | 2 | 1.0 |
Antigens, Surface/immunology | 3 | 1.0 |
Lymphocyte Function-Associated Antigen-1 | 3 | 3.0 |
Down-Regulation/genetics | 2 | 3.0 |
Antigens, CD44/biosynthesis/metabolism | 2 | 100.0 |
*Proto-Oncogene Proteins c-bcl-2 | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Neoplasms/*chemistry | 2 | 14.0 |
Endothelium/*immunology | 2 | 33.0 |
Endothelium, Lymphatic/*immunology | 2 | 66.0 |
DNA/isolation & purification | 2 | 1.0 |
Vehicle Emissions/*adverse effects | 2 | 6.0 |
Metalloendopeptidases/genetics/*metabolism | 2 | 5.0 |
Proteochondroitin Sulfates/metabolism | 2 | 16.0 |
Carcinoma, Hepatocellular/metabolism/*pathology | 2 | 11.0 |
Gelatinase A/metabolism | 2 | 3.0 |
Liver Neoplasms/metabolism/*pathology | 2 | 11.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Protein Array Analysis | 2 | 6.0 |
Adjuvants, Immunologic/pharmacology | 2 | 2.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Interleukin-8/*metabolism | 2 | 3.0 |
Hyaluronic Acid/*chemistry/metabolism | 2 | 100.0 |
Cross-Sectional Studies | 2 | 0.0 |
Interleukin-10/pharmacology | 2 | 2.0 |
Bone Marrow Cells/immunology | 2 | 5.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Dermatofibroma/metabolism/*pathology | 2 | 33.0 |
Skin Neoplasms/metabolism/*pathology | 2 | 5.0 |
Gelatinase B/*metabolism | 2 | 6.0 |
Carbamates/pharmacology | 2 | 18.0 |
Dipeptides/pharmacology | 3 | 7.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Cell Proliferation | 2 | 1.0 |
Mouth Neoplasms/*metabolism/pathology | 2 | 16.0 |
Urothelium/metabolism/pathology | 2 | 50.0 |
Membrane Proteins/biosynthesis | 2 | 3.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Endopeptidases/*metabolism | 2 | 1.0 |